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Chapter 1 
THE IMMUNE SYSTEM 
1.1 Introduction 
Vertebrates possess an immune system that discriminates between "self' and "non-
self'. Reactions mediated by the immune system may lead to elimination of foreign 
organisms, such as viruses, bacteria and parasites. 
Cells of the immune system produce cytokines, proteins that function as mediators 
between various cells of an organism. Due to recent progress in molecular biology a 
great number of cytokines has been identified and produced in large quantities by 
recombinant DNA techniques. One of the first cytokines that became available for 
research by these techniques was interferon-y (IFN-y). Based upon an impressive 
amount of in vitro experiments pleiotropic immunoregulatory and antiproliferative 
activities of IFN-y were found. Today, knowledge of the function of IFN-y in physio-
logic and pathologic conditions still mainly depends on extrapolation of in vitro 
findings. 
From a clinical point of view it is of great interest to analyse the effects of IFN-y in 
vivo. Being released by activated T cells at the centre of the immune response, this 
cytokine may play a pivotal role in immunoregulation. Thus, manipulation of its 
production might offer new perspectives for clinical entities in which suppression or 
stimulation of the immune system is essential, such as in organ transplantation and 
cancer immunotherapy. 
For example, rejection of a donor organ by the recipient is known to be an 
immunological process (1), initiated by T lymphocytes. These cells recognize antigenic 
components on the cell surface of "non-self' structures and initiate, by release of 
cytokines, including IFN-y, reactions that eventually lead to rejection of foreign cells. 
At present, T cell activation can adequately be prevented by cyclosporine, a potent 
immunosuppressive drug. However, cyclosporine surpresses T cell dependent immune 
functions non-specifically and thereby also reduces other host defense mechanisms 
necessary to offer resistance to invading micro-organisms. Further analysis of the 
function of cytokines released by activated T cells, such as interferon-y, may lead to a 
more selective manipulation of the immune system. 
Whereas organ transplantation might benefit from selective immunosuppression, 
selective immunostimulation might be to the advantage of cancer immunotherapy. 
During the last decades several theories have been postulated on cancer and the 
immune system. In the 1950's Foley demonstrated in mice that, after removal of a 
primary tumor, growth of reimplanted tumor tissue could be inhibited by allogenic-
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like immune reactions (2). It was found that cancer cells could express different 
proteins leading to altered antigenic cell surface components. These altered antigens, 
called tumor associated antigens (TAA) could induce allogeneic immune reactions. 
Various types of TAA were identified, dependent upon the tumor-inducing factor, i.e. 
chemical, physical or viral. 
In 1909 Ehrlich proposed the concept of an immune surveillance theory to explain 
how tumor growth could be prevented by the defense mechanisms of an organism (3). 
During the 1970s Burnett further developed this theory (4). He assumed that de novo 
tumor cells arose daily and were more or less antigenic to their host. Cancer cells 
would be recognized as "non-self' by T lymphocytes, be killed and eliminated via 
immunologic reactions. However, gradually it became clear that de novo tumor cells 
did not arise frequently (5) and that spontaneous tumors most often lack detectable 
surface antigens ( 6). Experimental studies demonstrated that the incidence of 
spontaneous tumors in immunodeficient mice was not higher than in normal mice (7) 
and that tumors which metastasized in normal mice failed to do so in immunocom-
promised mice (8). In clinical studies immunosuppressive therapy was found to 
enhance the risk of skin tumors and lymphomas, but not of other tumors of rapidly 
dividing tissues, as would be expected according to the immune surveillance theory 
(9,10). 
Hence, the theory was adapted to newer insights and the concept of natural 
resistance was developed. In this concept the importance of natural killer (NK) cells, 
known to be able to kill cancer cells without antigenic stimulation, was stressed. In 
the 1980's interest in cancer and immune reactions revived with the discovery of 
cytokines. Cytokines were demonstrated to kill cancer cells directly and, in addition, 
to stimulate immune functions, including NK activity. Interferons were one of the first 
groups of cytokines discovered and three different classes were identified, IFN-a, 
IFN-B and IFN-y. Of these, IFN-y was shown to have the strongest immuno-
modulatory and antiproliferative potency in vitro. 
The importance of these findings for immunoregulation and immunotherapy in vivo 
still has to be established. The aim of the experiments presented in this thesis was to 
determine the effect of IFN-y on immune functions and on cancer growth in vivo, 
using the rat model. 
As an introduction to the experiments a brief description of the main immune 
reactions is presented first. 
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1.2 Cells mediating immune responses 
Immunological reactions can be divided into a humoral and a cellular part. B lympho-
cytes are of main importance for humoral responses, whereas T lymphocytes, macro-
phages and natural killer cells are mainly involved in cellular reactions. Commonly 
accepted functions of these cells are described. 
B lymphocytes 
Humoral immunological reactions are provided by B cells that differentiate into 
antibody producing plasma cells in response to antigenic stimulation. In 1982 Grey et 
al (11) demonstrated that B cells act as antigen presenting cells (APC), processing 
antigen for specific T cells recognizing the presented antigen. It was shown that B 
cells can capture antigen present in the corporal fluid at very low concentrations with 
specific receptors (surface immunoglobulins) without the help of other APC, such as 
macrophages (12). The interaction between B and T cells provides the B cell with 
helper signals for proliferation, differentiation and specific antibody production. Thus, 
amplification of the humoral immune response occurs after B-T cell contact. 
Antibodies secreted by B cells bind specifically to inducing antigens, forming 
immune complexes. Subsequently, antigen-coated cells are damaged via complement 
dependent cellular cytotoxicity (CDCC) and antibody dependent cellular cytotoxicity 
(ADCC). In CDCC, the complement system, consisting of a series of protein com-
ponents acting in sequence, is activated via binding to an immune complex. Lysis of 
the cell to which the immune complex-complement system is attached, occurs through 
membrane destruction. In ADCC an effector cell mediates cytolysis after binding to 
an immune complex on a foreign cell via its receptor for the constant part (Fe) of 
immunoglobulin (Ig) molecules. 
T lymphocytes 
The population of T lymphocytes can be divided according to functional assays in 
helper T (Th), suppressor T (Ts) and cytotoxic T lymphocytes (CTL). As determined 
by these assays, activated helper T cells are essential for the activation of other 
immune mechanisms via release of several soluble, non-specific molecules (lympho-
kines). Ts-cells are capable to inhibit certain immune responses and CTL exert cyto-
toxic activity against cells with specific antigens. 
With the introduction of T cell cloning and the availability of monoclonal antibodies 
directed against molecules expressed on the cell membrane, T cells were redefined 
phenotypically according to the presence of specific cluster differentiation (CD) 
antigens. All T cells appear to have a common determinant, CD3, being an invariant 
component of the T cell receptor (TCR) complex. A subdivision into those expressing 
differentiation antigen CD4 and CD8 was made. Although functional and 
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phenotypical identification may not be considered to be identical, CD4 T cells are 
commonly referred to as Th-cel1s and CDS T cells as TsfC1L. 
T cells recognize antigen presented by APC in complex with cell membrane 
molecules coded by genes of the major histocompatibility complex (MHC) (13). CD4 
T cells mainly recognize antigen in association with MHC class II molecules, whereas 
CD8 T cells are restricted to MHC class I molecules (14). The accessory molecules 
CD4 and CD8 are thought to be responsible for the MHC restriction via a 
preferential binding site on certain parts of MHC molecules (15). In addition to the 
antigen-MHC class II complex the accessory molecules form a positive signal for the 
TCR during T cell activation. 
Studying the functional aspects of cloned murine CD4 T cells, Killar et al. (16) 
found a distinction into two major functional cell types. One providing help to B cells 
to produce specific antibody directed against extracellular pathogens (helper CD4 T 
cell or Th2) and the other mediating killing and delayed type hypersensitivity required 
for immunity against intracellular pathogens (inflammatory CD4 T cells or Th1). 
Mosmann and Coffman (17) demonstrated that the distinct functions of the two types 
of CD4 T cell lines correlated with the production of a distinct panel of lymphokines. 
For example, Th1 cells produce interleukin-2 (IL-2), lymphotoxin (LT) and interferon-
gamma (IFN-y), whereas Th2 cells produce among others IL-4. 
As in mice, subsets of CD4 T cells have been identified in rat and man. To date, no 
subdivision based upon differentiation antigens has been demonstrated for CD8 T 
cells. T cells that exert suppressive activity are identified in subsets expressing CD4 as 
well as CD8; cytotoxic T lymphocytes able to kill virus-infected cells and virally in-
duced tumor cells express the accessory molecule CD8. 
Natural killer cells 
The existence of a third category of lymphocytes different from either T or B cells is 
acknowledged (18). These cells are called natural killer (NK) cells, referring to the 
fact that they do not require prior sensitisation in vivo, but are already cytotoxic in 
vitro to a variety of cell lines. NK cells can be defined as CD3 and TCR negative 
large granular lymphocytes. In contrast to C1L, NK cells are not MHC class I 
restricted. In fact, there seems to be an inverse relationship between the MHC class I 
expression of cells and susceptibility to NK-cytotoxicity. Recently, Yeoman and 
Robins (19) demonstrated that treatment of rat tumor cell lines with IFN-y increased 
the expression of MHC class I molecules and reduced the sensitivity to NK-cytolysis. 
Interestingly, these treated cells were killed more effectively by C1L than untreated 
cells, suggesting a complementary function. In addition to NK cells, a minor 
population of CD3 T cells can be discerned that do not require MHC class I ex-
pression on cells either to exert cytotoxicity; these T cells express NK-like activity. 
NK cells may serve as a rapidly acting first line of defense mechanism involved in the 
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early destruction of malignant cells after entrance into the circulation. Studies on the 
survival of transplanted radiolabeled tumor cells in vivo revealed that 24-48 hours 
after inoculation twice as many cells of a NK-resistant tumor cell line were alive as 
compared to those of a NK-sensitive tumor cell line. The growth rate and doubling 
time of both tumor lines were similar (20). Notably, NK-mediated resistance against 
tumor growth in vivo can only be observed when a small number of tumor cells is 
inoculated. Studies in beige mice, that have an inherited low NK activity, showed an 
enhanced incidence in experimental and spontaneous metastasis of NK-sensitive B 16 
melanoma cells (21). In rat and mice depletion or inactivation of NK cells in vivo 
with antibodies enhances the survival of radiolabeled circulating tumor cells and the 
number of pulmonary and extra-pulmonary metastases of several tumors (22). These 
data strongly suggest that NK cells are of importance to prevent the take or seeding 
of circulating tumor cells. 
Cell lysis can occur directly via cell-cell contact or indirectly, e.g. via the release of 
tumor necrosis factor (TNF). The NK activity can be influenced by several 
lymphokines. Using cloned NK cell lines responsiveness was demonstrated to IL-3 for 
maintenance of growth and to IL-2 and IL-4 for activation of cytotoxicity. In vivo it 
has been shown that considerable synergies can be obtained in mouse peritoneal NK 
activity by local injections of IL-2 and IFN-y. 
Macrophages 
Monocytesjmacrophages are bone-marrow derived cells that can exert a variety of 
functions. They can act as APC, produce IL-l and trigger T lymphocytes. In response, 
the activated T cells produce a number of lymphokines that regulate monocyte 
activity. Macrophage chemotactic factor causes migration of monocytes to those sites 
where lymphokine production takes place, migration inhibiting factor (MIF) arrests 
monocytes at these locations and macrophage activating factor (MAF) induces lysis of 
intracellular organisms. MIF as well as MAP-like functions can be exerted by IFN-y 
(23). IL-2, stimulating all three populations of lymphocytes, may influence the activity 
of monocytes as well. Malkovsky et al. (24) demonstrated that certain human mono-
cytes can display an enhanced cytotoxic activity in response to IL-2, but not to IFN-y. 
Activated macrophages have an enhanced expression of certain cell membrane 
proteins, such as MHC class II molecules and Fc-receptors. They express an increased 
phagocytosis, non-specific antimicrobial activity and tumor cytotoxicity. The release of 
cytokines, such as tumor necrosis factor, is enhanced, which may contribute to the 
killing of tumor cells. 
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1.3 Determinants of immune responses 
In the 1980s detailed information became available on the mechanisms by which 
immune cells are able to recognize foreign antigens. While B cells recognize antigen 
directly via immunoglobulin molecules, T cells can only recognize antigen in asso-
ciation with "self' molecules coded by genes of the MHC. These molecules play a 
pivotal role in antigen activation of T cells. They can be divided in class I and class II 
molecules according to their structure, function and tissue distribution. MHC class I 
molecules are expressed on most, if not all nucleated cells and function as receptors 
for peptide fragments, such as degradation products of viral and endogenously syn-
thesized proteins. Antigen-specific CDS T cells can recognize these MHC class !-
peptide complexes and are triggered by this complex to execute their effector func-
tion, i.e. lysis of the target cell. 
MHC class II molecules are normally expressed on a limited number of cells, 
including B cells, macrophages, dendritic and Langerhans cells (25). Antigen in 
association with MHC class II molecules on APC is mainly recognized by CD4 T cells 
leading to release of lymphokines regulating antigen-specific immune reactions such 
as expansion of CTL clones and enhancement of B cell responses. In the artificial 
situation of organ transplantation a donor MHC-peptide complex can induce allo-
reactive responses, thereby making complex formation of the donor peptide with the 
recipients MHC-molecules not a prerequisite for immune activation. 
Although MHC-antigens are of major importance for the outcome of an allograft, 
other antigens may have an effect as well. In the mouse system another set of 
determinants has been demonstrated that can function as strong stimuli for prolife-
rative responses of T-cells. They are called minor lymphocyte stimulating (Mls) 
antigens and defined by their ability to induce T cell responses in mixed lymphocyte 
reactions of MHC-identical strains (26). Furthermore, tissue specific antigens have 
been identified for skin, heart, liver and pancreas (27), as well as endothelial cells 
(28). These antigens are of minor importance for the rejection of an allograft 
compared to the MHC-antigens, except when presensitization has occurred. 
1.4 Cell signaling and immune regulation 
Activation, proliferation and differentiation of cells mediating immune reactions is 
controlled by a complex system of molecular mechanisms. Originally, these molecules 
were called interleukins, referring to their function as intermediates in the co-
operation between leukocytes. However, since the first interleukins have been dis-
covered a variety of (glyco )proteins have been identified that are produced by and 
regulate the growth and immune function of other cells than lymphocytes. Thus, the 
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term "interleukin" has become broadened in its use to encompass these other mole-
cules. Strictly speaking the word interleukin is a misnomer to define the entire group 
of immunoregulating proteins and is at present replaced by the term cytokines. 
During the 1980s an impressive number of cytokines have been discovered and 
made available for study by recombinant DNA techniques, such as interleukins, 
colony stimulating factors (CSF), tumour necrosis factors (TNF), and interferons 
(Table 1.1) (29). 
Table 1.1 Main activity of various cytokines 
Name 
IL-1 
IL-2 
IL-3 
IL-4 
IL-5 
IL-6 
IL-7 
TNF-a, -B 
GM-CSF 
G-CSF 
M-CSF 
IFN-a, -B 
IFN-y 
main activity 
proinflammatory protein 
activation ofT lymphocytes 
growth factor for activated T cells 
multipotential hematopoietic cell 
growth factor 
B cell growth factor 
induction of IgE production 
activation, growth and differentiation 
factor for B cells 
differentiation of eosinophils 
proinflammatory protein 
stimulation of B cells 
weak antiviral activity 
growth factor for hybridomajplasmocytoma 
T and B cell differentiation 
proinflammatory proteins 
cytotoxic activity 
catabolic activity 
growth and stimulation factor for 
hematopoietic cells (granulocytes (G) 
and macrophages (M)) 
antiviral activity 
antiproliferative activity 
immunomodulation 
immunomodulation 
antiproliferative activity 
antiviral activity 
In vitro studies, mainly performed with mouse and human cell lines, have shown 
that many of these cytokines have pleiotropic effects, such as IFN-y, and more or less 
interchangeable biological activities, e.g. IFN-y as well as IL-2 may enhance monocyte 
activity. Multiple cytokines may be required for the development of an immune cell, 
such as the B lymphocyte, where a series of factors, including IL-l, IL-2, IL-4, IL-5, 
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IL-6 and IFN-y, is invoked to control activation and differentiation (30). For example, 
the production of different Ig is induced by distinct cytokines: in mice IL-4 induces 
IgG1 and IgE production, IL-5 lg.A, and IFN-y IgG2. 
These data clearly demonstrate the complexity of immunoregulation by the 
cytokine system. And although cell line studies have produced an overwhelming 
amount of detailed information many aspects of immunoregulation are still poorly 
understood. 
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Chapter 2 
INTERFERON-y 
2.1 Introduction 
In 1957 Isaacs and Lindenmann (1) discovered a protein, designated interferon, that 
could confer resistance upon cells against a variety of viruses. In addition to its 
antiviral activity (2), IFN was found to inhibit cell growth (3) and influence many 
activities of cells belonging to the immune system ( 4-6). During the last decade 
multiple biologic effects of IFN were demonstrated (Table 2.1) (7). Most recently, a 
protein secreted by the early embryo and involved in maternal recognition of 
pregnancy was shown to be an IFN (8,9). 
Table 2.l.Biological activities of IFN 
antiviral 
antitumor 
antimicrobial 
MHC antigen expression 
cell differentiation 
cell growth inhibition 
enhancement of ADCC 
enhancement of NK-activity 
macrophage activation 
modulation of B cell response 
inhibition of T suppressor cells 
enhancement of T cell cytotoxicity 
Today, interferons are defined as proteins synthesized by vertebrate cells after 
exposure to a variety of stimuli and able to exert a broad spectrum of biological 
activities. Three functionally related, but antigenically distinct groups of proteins, 
designated IFN-a, -B, and -y (10) are identified in all mammalian species investi-
gated. 
On basis of its genetic origin, production and pleiotropic effects IFN-y can be 
considered as a distinct entity when compared with other IFN. With the availability of 
recombinant IFN-y (11-15) an impressive amount of research has been performed in 
vitro and in vivo to elucidate its physiologic role and potential therapeutic use. 
This chapter was published in a modified form in Immunobiology 179: 456-473, 1990 
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2.2 Molecular biology 
2.2.1 Induction and expression 
IFN-a and -.B are structurally related (16) and their genes located on the same 
chromosome (9 in man) (17), indicating their origin from a common ancestral gene 
(18). IFN-y has a very limited structural homology to IFN-a and -.B; its genetic code 
is located on a different chromosome (12 in man) (19-21). There is evidence for only 
one IFN-y gene in all species analysed. The gene codes for single polypeptides with 
an overall length of 146, 137 and 136 amino acids for human, rat and mouse IFN-y, 
respectively. In man, the protein has a molecular weight of 17.147 daltons (22,23). In 
all three species the IFN-y molecule contains two potential glycosylation sites. 
Dependent upon the carbohydrate groups attached at these sites IFN-y can be 
secreted as a glycoprotein with a different molecular weight, i.e. in man 20.000 or 
25.000 dalton (24). The presence of carbohydrate moieties on IFN-y affects its 
biochemical, but not its functional properties. Glycosidase treatment of IFN-y does 
not reduce its antiviral activity, affect the interaction with a specific antibody or 
change its target cell specificity (25). 
IFN-y is produced by activated T cells and probably by NK cells (26,27). Its 
production can be induced by many and diverse substances such as mitogens, 
antigens, allogeneic molecules coded for by the MHC complex (28) and antibodies 
directed against lymphocyte surface antigens (29). 
The interaction between an IFN-y inducer and a sensitive T cell leads to 
derepression of the specific genes, transcription of the eDNA sequence, de novo 
synthesis of mRNA and protein synthesis. In primary and secondary anamnestic 
immune responses, different kinetics of production can be distinguished, varying from 
days to hours, respectively (30,31). 
Different T cell subpopulations, phenotypically defined as helper cells and 
suppressor/cytotoxic cells, may produce IFN-y, depending on the type of inducing 
stimulus (32,33). Notably, these cells can also produce IFN-a and -.B, if stimulated by 
viral antigens, demonstrating an independent regulation of the distinct IFN-genes 
(34,35). 
The production of IFN-y is mediated by other cytokines released by cells of the 
immune system. Interleukin 2 (IL-2), mainly secreted by helper T cells (36) and 
interleukin-1 (IL-l), secreted by antigen-presenting cells, can enhance IFN-y release 
directly as well as indirectly. IL-l induces the expression of IL-2 receptors (IL-2R) in 
T cells that recognize the appropriate antigen (37). Subsequently, IL-2 promotes the 
proliferation of IL-2R positive cells and enhances the secretion of IFN-y (38). The 
intracellular pathway induced by IL-2 to regulate the production of IFN-y acts 
independently from the mechanism by which IL-2 enhances cellular proliferation (39). 
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Although IL-2 is significantly involved in the production of IFN-y, its requirement is 
not an absolute one (40,41). 
2.2.2 Receptor interaction 
IFN-molecules interact with cells by binding to specific membrane receptors ( 42). All 
human cells tested so far carry a receptor for IFN-y characterized by high affinity and 
specificity to the ligand. The observed species-specificity normally associated with 
IFN-y seems to be dependent on the interaction of the molecule with the cell 
membrane-receptor. Sanceau et al. (43) demonstrated that murine cells transfected 
with a eDNA encoding for a human IFN-y protein, accumulated the protein inside 
the cell, did not secrete it, and yet developed an antiviral state. In addition, human 
and murine IFN-y proteins encapsulated within liposomes can induce activation of 
human as well as murine macrophages after phagocytosis (44). 
Two molecular forms of the human IFN-y receptor have been identified (45). The 
two receptor types differ in molecular weight, stability to acid and regulation of 
receptor expression. It is suggested that receptor variability may contribute to the 
different activities of IFN-y on different cell types. The transmembranous signal 
produced by ligand binding leads to intracellular signals, mediated by and requiring 
the presence of other factors ( 46). Interaction of IFN-y with its receptor as such may 
not be sufficient to initiate cell activation, as demonstrated by Hamilton et al. ( 47) 
who investigated the receptor mechanism of macrophages derived from AjJ mice. 
The functional and biochemical reactions of these macrophages are deficient in 
response to IFN-y when compared with macrophages of normal mice. It could be 
demonstrated that this was not due to different expression of the IFN-y receptor or to 
altered affinity of the receptor for its ligand. Using another stimulus (ionophore 
combined with phorbolmyristic acetate), functional competence, comparable to the 
IFN-y induced in normal macrophages, could be achieved. 
Binding of IFN-y to its receptor is followed by receptor-mediated endocytosis and 
ligand degradation ( 48). It is not clear whether IFN necessarily needs to be internali-
zed to exert its biologic effect ( 49). Experiments with anti-receptor antibodies suggest 
that activation of the receptor may be sufficient to initiate transmembranous and 
intracellular signalling. However, if IFN-y is manipulated into a cell via liposomes, 
thus bypassing the receptor, biologic effects can be induced too, indicating the 
existence of different mechanisms. 
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2.2.3 Biochemical actions 
Receptor-bound IFN-y initiates a series of metabolic modifications leading to the 
expression of a large series of genes, de novo synthesis of RNA and synthesis of 
polypeptides. Like other types of IFN, IFN-y induces the production of at least 12 
distinct proteins (50). A protein kinase (51), a nuclease (52) and a mRNA methy-
lation pathway (53) have been identified. Viral protein synthesis is inhibited, probably 
by inhibition of viral RNA translation (54). 
All types of IFN can down-regulate protein synthesis and it has been suggested by 
Clemens (55) that such an effect on oncogene expression might be an important 
pathway by which IFN exerts antitumour activity. In agreement with this theory, Jonak 
and Knight (56) observed concurrent inhibition of cell growth and oncogene expres-
sion by IFN-13 added to a cell line with abnormal oncogene expression. However, 
Chang et aL (57) found that IFN-y treatment of a human carcinoma cell line resulted 
in growth inhibition and enhanced oncogene expression. Thus, IFN-y can also exert 
anti-proliferative effects while oncogene expression is increased. 
2.3 Biological effects 
2.3.1 Antiviral action 
In contrast to other interferons, IFN-y is not primarily an antiviral agent. Within 
hours after viral infection, IFN-o: and -13 are released by cells at the portal of viral 
entry (e.g. epithelium of the upper respiratory tract) and rapidly (58) inhibit virus 
replication by the induction of enzymes that interfere with the translation of viral 
RNA (59). 
In physiologic conditions IFN-y is produced much later during the course of a viral 
infection than IFN-o: and -13. Viral antigens that have penetrated into the circulation 
will be mitogenic to lymphocytes and induce IFN-y production. Antiviral activity of 
IFN-y has been demonstrated in vitro (60) and in vivo (61). IFN-y has been demon-
strated to potentiate the antiviral activities of IFN o:jB (62). Rubin and Gupta (60) 
compared IFN o:/B and IFN-y for relative antiviral activities against different viruses 
using human fibroblast cell lines. Replication of vesicular stomatitis and encepha-
lomyocarditis virus was found to be inhibited more strongly by IFN o:/13, whereas 
reovirus and vaccinia virus displayed more sensitivity to IFN-y treatment. Thus, 
viruses differ in their sensitivity to IFN-o:/B or -y. During a viral infection the synergy 
between distinct types of IFN will be most effective. IFN-o:/13 will act as a first line of 
defense, secondarily amplified by antiviral activities of IFN-y. 
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2.3.2 Immunomodulatory action 
Action on B lymphocytes 
IFN-y is one of the lymphokines released by T cells upon T-B cell and T cell-
macrophage interaction. Its role in B cell maturation is not well established. In 19S4 
Sidman et aL (63) described IFN-y as being one of a family of B cell maturation 
factors. It was suggested that IFN-y was functioning as an obligatory early (64) and 
late-acting ( 65) B cell differentiation factor. 
Recent studies indicate that IFN-y in fact inhibits the proliferation of resting B cells 
that can be stimulated by B cell stimulatory factor 1 (BSF-1), also called interleukin-4 
(66). The identification of two subsets of helper T cells (Th1 and Th2) can explain 
these seemingly contradicting results. Th1 mainly secretes IL-2 and IFN-y, whereas 
Th2 mainly produces BSF-1. Reynolds et aL (67) nicely demonstrated, using cloned 
murine cell lines, that the supernatant of Th1 cells is able to induce proliferation of B 
cells when monoclonal antibodies directed against IFN-y are added, whereas the 
activity of B cell stimulating Th2 supernatant can be reversed by addition of IFN-y. 
Thus, it was shown that both helper T subsets produce B cell growth and maturation 
inducing factors and that IFN-y, produced by Th1 cells, is a potent inhibitor of B cell 
activation, especially for the IgG1 and IgE response. 
However, the relationship between IFN-y and B cells is more complex. IFN-y also 
plays a role in phenotypic changes of B cells and in the differentiation into Ig-
secreting plasma cells. Recently, Snapper and Paul (6S) demonstrated that IFN-y 
stimulates the expression of Ig of the IgG2a isotype and inhibits the production of 
others. By contrast, IL-4 markedly inhibits IgG2a expression, but promotes the 
expression of IgG1 and IgE, which in turn is depressed by IFN-y. Thus, IFN-y and IL-
4 act as antagonists in the regulation of Ig-isotype responses. 
Action on T lymphocytes 
IFN-y is one of the lymphokines involved in the generation of CTL from resting 
precursors (69-72). Bach et aL (73) investigated the relationship between various 
lymphokines and the stage of differentiation of T cells. Using monoclonal antibodies 
directed against the CD2 surface molecule present on T cells, a proliferative response 
in CD4 as well as CDS T cells was induced without the induction of cytotoxicity. 
Subsequent addition of IFN-y or IL-2 to these activated cells led to the acquisition of 
cytotoxicity by CDS T cells, but not CD4 T cells. In contrast to IL-2, IFN-y did not 
have the capacity to stimulate further proliferation of activated cells. 
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Action on NK-cells 
During the last decade much attention has been given to the NK-IFN system. Mice 
with absent or low NK-activity have an increased incidence of experimental and 
spontaneous metastasis of NK-sensitive B16 melanoma cells (74). Bloom (75) stressed 
the immunomodulatory effect of IFN on NK-activity. Herberman (76) suggested that 
deficiencies of the NK-IFN system could play an important role in immune surveil-
lance against tumours. Different findings were reported on the NK-IFN system in pa-
tients with advanced cancer disease. Catalona et al. (77) demonstrated a significant 
enhancement of NK-activity by IFN-y, and Weigent et aL (78) demonstrated that 
IFN-y had a 50-fold greater ability to enhance NK-activity in human lymphocytes 
than IFN ajB. Enhancement of NK-activity in response to IL-2 was suggested to be 
an IFN-y mediated effect (79). Analyzing lymphoid cytotoxicity in mice, Braakman et 
al. (80) demonstrated that at least three phenotypical distinct subsets of NK-cells 
could be identified. Addition of IL-2 and/or IFN-y resulted in enhancement of NK-
activity in all subsets. In one subset, however, the absence of an IFN-y receptor could 
be demonstrated and NK-activity of cells belonging to this category could only be 
enhanced by IL-2. Furthermore, the IFN-y induced enhancement of NK-activity of 
the other subsets could be completely inhibited by antibodies directed against IFN-y. 
These antibodies did not interfere with IL-2 cytotoxicity. Thus, this study indicates 
that distinct lymphoid subsets have a variable expression of lymphokine-receptors and 
enhancement of NK-activity by IL-2 is only partially mediated by IFN-y. Shalaby et al. 
(81) demonstrated that the NK-activity of peritoneal derived cells of mice treated 
with IFN-y or IL-2 alone exhibited significantly enhanced cytolytic activities. 
Treatment of mice with both lymphokines in sequence resulted in a synergistic 
enhancement of NK-activity if IFN-y was administered 24 hours before IL-2. The 
time-dependent relationship between both lymphokines may be explained by the 
induction of IL-2 receptors by IFN-y. 
In 1978 Trinchieri and Santoli (82) reported that IFN could protect tumor cells 
from NK-mediated cytolysis. Recently, the results of this contradicting report were 
clarified by the work of Yeoman and Robbins (83). They demonstrated that IFN-y 
treated target cells become less sensitive to NK-cytotoxicity, if the expression of MHC 
class I molecules is concurrently enhanced. 
Action on macrophages 
IFN-y has the ability to induce differentiation of myelomonocytic cells (84) and to 
exert pleiotropic effects on mature macrophages (85,86). It is well established that 
IFN-y induces enhanced MHC class II and Fc-receptor expression, inhibition of bac-
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terial growth, phagocytosis, tumor cytotoxicity and cytokine release, such as TNF. 
Celada et al. (87) found that the receptor for IFN-y on monocytes differs from that 
on non-hematopoietic cells. Both receptors behave as hormone receptors, i.e. binding 
of the ligand is followed by receptor-mediated endocytosis and ligand degradation 
with release of degradation products (45). However, when tested by excess of the spe-
cific ligand, receptor down-regulation can be observed in the case of monocytes, but 
not in the case of non-hematopoietic cells (88). 
In 1983 Schultz and Kleinschmidt (89) demonstrated that MAF is identical to IFN-
y. Bancroft et aL (90) discovered the existence of aT cell independent mechanism of 
macrophage activation in mice having no detectable B or T cell functions due to an 
inherited severe combined immunodeficiency mutation. With monoclonal antibodies 
against IFN-y, this lymphokine was identified as macrophage activating factor, leading 
to enhanced expression of MHC class II expresssion and inhibition of bacterial 
growth. Leu and Herriott (91) demonstrated that IFN-y induces specific antibody-
dependent and non-specific killing of bacteria and tumor cells. In the murine model, 
proteins distinct from IFN-y have been identified that are able to execute MAF-like 
activity. Meltzer et a!. (92) found that a murine cloned T cell line treated with 
phorbol myristate released a factor that activated macrophages for non-specific tumor 
cytotoxicity. This factor was physicochemically and biologically different from IFN-y 
or one of its breakdown products. 
In the human system similar observations have been made. Malkovsky et al. (93) 
demonstrated that certain human monocytes can display an increased cytotoxic acti-
vity as direct and rapid response to IL-2, but not to IFN-y. Futhermore, IL-2 may 
enhance the production of TNF-a and -B by human monocytes in a similar way as 
IFN-y (94). Although activation of macrophages seems to be one of the major 
functions of IFN-y, other cytokines may exert MAF-like activity as well. 
IFN-y is thought to play a pivotal role in the induction of antigen processing and 
signalling by APC. It is well established that IFN-y rapidly enhances the expression of 
MHC class II molecules on the cell membrane of macrophages. The relevance of this 
mechanism was demonstrated by Gonwa et al. (95), who showed that the antigen-
presenting capacity of human monocytes correlates with the expression of MHC class 
II molecules. In addition, IFN-y is known to enhance the release of IL-l (96), a 
lymphokine acting as accessory signal in T cell activation. These observations strongly 
favor the concept that IFN-y is involved in macrophage activation. 
Action on the expression of cell membrane molecules 
IFN-y has the capacity to induce the expression of cell membrane molecules, 
including IgG receptors (97), tumor associated antigens (98) and molecules encoded 
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by MHC genes (99). Following treatment with IFN-y, an increased expression of 
MHC class I molecules has been detected on a wide variety of cells. In a similar way 
class II expression may be enhanced by IFN-y. For MHC class II antigens a qualita-
tive change can be observed when cells that are normally class II negative are 
induced by IFN-y to express class II molecules de novo. 
IFN-y has a strong effect on the expression of MHC class II molecules of a large 
number of cell types (100, 101) among which endothelial cells. Since antigen recogni-
tion by cytotoxic and helper T cells is restricted to class I and II molecules, respecti-
vely, the qualitative and quantitative variation in MHC antigen expression may have 
important immunomodulatory effects. Janeway et aL (102) demonstrated that 
lymphocyte reactions are enhanced when the number of MHC molecules expressed 
on allogeneic cells is increased. Thus, the release of IFN-y by activated T cells during 
ongoing alloreactive responses may lead to enhanced expression of MHC molecules 
on target cells and thereby to amplification of these responses. 
IFN- r and autoimmune disease 
Among many other humoral factors, such as prostaglandins, leukotrienes and 
corticoids, IFN play a modulatory role in the pathogenesis of inflammation (103). 
Billiau et aL (104) reported that IFN-y may act as a positive factor triggering or 
promoting the inflammatory response. Studying the Schwartzman reaction in mice, it 
was found that the local hemorrhagic and necrotic reaction, normally observed if 
bacterial endotoxin is given intravenously 24 hours after an intradermal injection of 
toxin, was completely absent in mice treated systemically with monoclonal antibodies 
directed against murine IFN-y. Antibodies against IFN-ajB had no effect. This 
finding suggests that IFN-y may function as an up-regulator of the primary phase of 
an inflammatory response. 
In addition to its role in the local inflammatory response to exogenous agents, IFN-y 
may be involved in the reaction to endogenous stimuli as well. It is well established 
that the first step in the induction of immune responses, whether humoral or cell 
mediated, requires the interaction between antigen-presenting cells, expressing MHC 
class II molecules, and MHC-restricted T cells. As mentioned above, the induction of 
MHC class II expression seems to be one of the major functions of IFN-y. It has 
been found that in certain autoimmune diseases, such as thyroiditis (105), insulin-
dependent diabetes (106) and rheumatoid arthritis (107), MHC class II molecules are 
expressed by endocrine epithelial cells that normally do not express them. These class 
II molecules appear to have a normal protein structure. Weetman and Rees (108) 
reported MHC class II antigen induction on thyrocytes by IFN-y, while Londei et al. 
(109) demonstrated that human thyroid cells expressing class II antigens may act as 
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APC activating T cells. In a recent study CD4 T cell mediated killing of antigen-
presenting cells was described (110). Once activated by APC expressing the appropri-
ate class II molecule and antigen, CD4 T cell clones autonomously killed their target 
APC. Furthermore, normal macrophages treated with IFN-y to increase class II 
expression, were killed too. The authors suggested that target tissues in autoimmune 
diseases, such as thyroiditis, act as APC for infiltrating autoreactive immune cells, 
which in tum produce cytokines, leading to enhanced expression of class II molecules, 
thus maintaining ongoing autoimmune responses. 
The initiating event leading to this self-destructing mechanism may be caused by 
viral infection. Studying the pathogenesis of beta-cell destruction in insulin-dependent 
diabetes Campbell et al (111) showed that viruses may increase MHC antigen 
expression independent of and before the action of cytokines such as IFN-y and TNF. 
It should be noted that stimulation by IFN-y alone may not be sufficient to induce 
class II expression in all cell types, i.e. islet beta cells. In these cells TNF or 
lymphoto:xin (LT) are required in addition to IFN-y to induce class II expression 
(112). Since activated T cell clones may produce TNF and LT as well as IFN-y (113), 
it can be speculated that these cytokines are released at the same time during an 
immune response and act synergistically upon the target cell, a process which may 
have important consequences for cell destruction in autoimmune diseases. 
2.3.3 Antitumor action 
Several mechanisms may be involved in the antitumor activities of IFN-y. Depending 
upon the tumor cell line tested, IFN-y may have direct antiproliferative effects on 
cells mediated through specific membrane receptor binding. A relationship between 
the number of cell membrane receptors and the efficacy of IFN-y has been demon-
strated by Uecer et al. (114). IFN-y has been shown to have a stronger antitumor ef-
ficacy on a number of human and mouse tumors than either IFN-a or -B (115,116). 
IFN-y may exert a direct cytolytic effect on certain tumor cell lines, as shown with 
murine and human preparations. Tyring et al (117) investigated the cytolytic activity 
of murine IFN-y on 11 murine tumor cell lines and observed a 20-fold difference 
between the most sensitive and most resistant cell type. Synergistic effects of IFN-y 
and IFN-a or -B were demonstrated and sublytic concentrations of IFN-y combined 
with another IFN did lead to cytolysis. Enhancement of cytotoxicity was also observed 
when sublytic concentrations of IFN-y were combined with spleen cells or peripheral 
blood mononuclear cells (118). This effect might be caused by reinforcement of the 
cytolytic activity of IFN-y on target cells and/or activation of cellular cytotoxicity of 
added mononuclear cells. 
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Using murine lymphoma cells, Suzuki et aL (119) observed IFN-y induced cell-
mediated cytotoxicity in the absence of a direct effect of IFN-y on the tumor cells. 
The lymphoma cells used are characterized by growth inhibition in peritoneal cell 
cultures prepared from mice harboring the tumor cells in their peritoneal cavity in a 
dormant state. Treatment of these cultures with antibodies to IFN-y and TNF 
receptors (but not with antibody to IL-2 receptors) eliminated the restraint on tumor 
cell growth, permitting proliferation. The lymphoma cells appeared to be resistant to 
direct treatinent with IFN-y and/or TNF. Treatment of peritoneal cultures from 
tumor-dormant mice with IFN-y resulted in a marked inhibition of tumor cell growth. 
Since no soluble tumor-cytotoxic factors could be detected in the cell cultures, these 
findings suggest that the IFN-y induced cytotoxicity was cell-mediated. 
Several in vivo studies demonstrated that in vitro insensitivity to IFN-y does not 
exclude effectiveness of in vivo treatlnent. Belardelli et al. (120) injected IFN-resistant 
and IFN-susceptible leukemia cells into mice treated with IFN. Treatl.nent was active 
against both cell types, suggesting that host defense mechanisms were involved in the 
antitumor action of IFN. Similar findings were reported by our group (121) using a 
rat colon carcinoma cell line insensitive to in vitro treatment by IFN-y. It was found 
that animals treated with IFN-y developed a significantly lower number of liver 
metastases after injection of tumor cells into the portal vein. These findings strongly 
suggest that IFN-y may have antitumor effects through activation of effector cells, 
such as T cells, NK-cells and macrophages, of which is known that they can destroy 
tumor cells in vitro. 
Down-regulation of oncogene expression has been speculated to be another 
mechanism by which IFN-y may exert antiproliferative efficacy. Einert et al. (122) 
described a relationship between reduction of oncogene expression ( c-myc) by IFN -y 
and arrest in the G0/G1 cell cycle, indicating inhibition of proliferative activity. The 
reduction of oncogene expression could be reinforced by addition of TNF. 
It should be noted that these findings may depent on the cell line used. Other 
investigators have reported growth inhibition of a carcinoma cell line concurrently 
with an enhancement of oncogene expression (123). Whatever the mechanism 
involved, as yet the effect of IFN-y on oncogene expression is not clear. 
2.4 Clinical studies 
The results of the first phase I trials investigating toxicity of IFN-y in patients were 
reported in 1983, utilizing partially purified, non-recombinant IFN-y preparations. 
Adverse effects reported included flu-like symptoms such as fever, chills, fatigue and 
anorexia, nausea and diarrhea, all reversible on cessation of the drug. An in vivo half-
life of 30-60 min was found (124), based on serum antiviral activity. To obtain higher 
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serum concentrations during an extended period of time without serum peak levels 
continuous infusion instead of bolus injections were designed. Gutterman et aL (125) 
observed that low dosages of IFN-y not leading to measurable serum levels, did cause 
clinical toxicity, such as chills and fever. This finding suggests that low doses of IFN-y 
may be sufficient to induce physiological effects. 
Reports on phase I studies using recombinant IFN-y products described clinical 
toxicities identical to those observed in studies in which partially purified IFN-y 
preparations were used. Thus, the adverse effects are indeed caused by IFN-y itself 
and not by contaminating products. Toxic effects appear to be independent of the 
route of administration. Using high dosages of IFN-y, dose-related toxicities were 
reported, including leukopenia, transaminase elevations, proteinuria, respiratory 
distress, uncontrollable pyrexia and hypotension (126,127). 
Kleinerman et aL (128) examined the antitumor properties of blood monocytes 
obtained from cancer patients undergoing recombinant IFN-y treatment. Remarkably, 
monocytes of patients treated with low doses of IFN-y showed an enhanced 
cytotoxicity, whereas those of patients treated with high doses showed a reduced one. 
Studying biological activities of IFN-y in patients with melanomas, Maluish et a/.(129) 
observed immunomodulatory effects of IFN-y treatment in early stage malignancies. 
Macrophage activation, enhancement of Fe receptor expression on mononuclear cells, 
increased NK cell cytoxicity and enhancement of MHC class II antigen expression 
were demonstrated after IFN-y treatment. 
Recently, the first results of phase II trials using riFN-y have been published. 
Responses have been observed in patients with distinct pathological entities. Garnick 
et a!. (130) reported antitumor activity in patients with advanced metastatic renal cell 
carcinoma, giving recombinant IFN-y at a daily dose of 103-3x103 microgram/m2 for 7 
days, which was repeated every 2 to 3 weeks. Of 41 patients evaluable for response, 
one patient demonstrated a complete response 6 months in duration, while three 
other patients showed a partial response. The responders were patients with 
pulmonary, lymphatic or hepatic metastases. In this study osseous and primary renal 
lesions were refractory to treatment. Most recently, Sedman eta!. (131) reported that 
IFN-y can augment the in vitro cytotoxic activity of IL-2 activated killer cells of 
patients with gastrointestinal cancer. Whether this finding may have therapeutic 
consequences, remains to be determined. 
A number of studies have reported positive effects of IFN-y treatment in other 
diseases, such as rheumatoid arthritis (132,133) and relapsing ovarian carcinoma 
(134). Murphy eta!. (135) investigated the incidence of bacterial infections in patients 
with the aquired immunodeficiency syndrome (AIDS) treated by IL-2 or IFN-y. A 
marked disparity was noted in favor of IFN-y treated patients, who suffered less 
frequently of bacterial infections. 
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Today however, no convincing results have been published about diseases that can 
be successfully treated by single IFN-y therapy. Considering the complexity of cellular 
and cytokine interactions within the immune system, it must be realized that the 
administration of only one of its components, such as IFN-y, may not be sufficient to 
achieve therapeutic effects. At present studies are being performed to investigate the 
antitumor effect of IFN-y in combination with other cytokines or treatment moda-
lities. 
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Chapter 3 
OBJECTIVES OF INVESTIGATION 
In the following chapters studies are described in which various immunological and 
antitumor effects of rRIFN-y are investigated in vivo. The aims of the studies are, 
respectively: 
- To assess the effect of rRIFN-y on immune functions, including NK cell activity, 
phagocytosis and mitogen-induced blastogenesis (Chapter 4). 
- To assess the effect of rRIFN-y on MHC class II antigen expression in different 
organs of various rat strains (Chapter 5). 
- To study cardiac allograft survival in recipients treated with rRIFN-y (Chapter 6). 
- To study the effect of donor pretreatment with rRIFN-y on MHC class II antigen 
expression on dendritic-like cells (Chapter 7) and endothelial cells (Chapter 8) in 
heart tissue, and the effect of donor pretreatment on cardiac allograft rejection by 
unmodified recipients. 
- To study the influence of the recipient's immune status on the rejection of skin 
allografts derived from rRIFN-y pretreated donors (Chapter 9). 
- To determine the antitumor capacity of rRIFN-y in a rat colon adenocarcinoma 
model (Chapter 10). 
- To determine the toxicity and antitumor capacity of rTNF in combination with 
rRIFN-y (Chapter 11). 
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Chapter 4 
IMMUNOMODULATION BY rRIFN-y IN VIVO 
Abstract 
Recently, recombinant rat IFN-y (rRIFN-y) became available, enabling extensive studies 
on its physiologic role in rats. In the experiments described here a LEW rat model was 
used to determine the efficacy ofrRIFN-y on immune functions in vivo. LEW rats were 
treated with rRIFN-y by continuous intravenous infusion at a dosage of 1.5 x Hf 
U jkg/hr for 2 consecutive days. Twelve hours after cessation of rRIFN-y administration, 
immune functions, including NK cell activity, phagocytosis and mitogen-induced 
blastogenesis, were assessed. All experimental animals displayed a marked reduction in 
the number of peripheral blood and bone marrow cells when compared with controls 
(p < 0.005). Assessment of immune functions revealed a significant enhancement of NK 
cell activity (p<O.OOl), phagocytosis (p<0.05) and mitogen-induced blastogenesis 
(p<0.05). These findings indicate that rRIFN-y, when given in high dosages, has a 
stimulatory effect on various immune functions, which substantiates its important 
immunological role in vivo. 
This chapter has been published in J Interferon Res 10: 203-211, 1990 
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Introduction 
IFN-y is a lymphokine predominantly produced by activated T lymphocytes. A multitude 
of biologic activities exerted by IFN-y on cells of the immune system is well documented. 
It has been demonstrated that IFN-y is involved in proliferation and differentiaton of 
helper (CD4) and cytotoxic (CD8) T lymphocytes and the acquisition of cytotoxicity by 
CD8 T lymphocytes (1,2). IFN-y has been shown to enhance the activity of NK cells (3-
5), monocytic cytotoxicity (6,7) and macrophage activity (8,9). In addition, it is well 
documented that IFN-y can exert pleiotropic effects on cells not belonging to the 
immune system. A direct cytotoxic effect on certain tumor cell lines has been reported 
(10,11). Furthermore, IFN-y may induce the expression of surface antigens on a diversity 
of cell types, including tumor cells (12,13), endothelial cells (14,15) and macrophages 
(16,17). 
The relevance of these distinct in vitro findings for the physiologic efficacy of IFN-y 
in vivo remains to be determined. Because of its species specificity human IFN-y cannot 
be tested appropriately in rats or mice. Recent advances in molecular biology have 
resulted in recombinant DNA-derived rat IFN-y (18). By the introduction of this recom-
binant lymphokine, the rat system with its cancer-, infection- and transplantation models, 
has become accessible to study the biologic activities of IFN-y in vivo. These studies may 
contribute considerably to our understanding of IFN-y and offer new perspectives 
towards the clinical application of human IFN-y. In the present study we demonstrate 
the in vivo efficacy of rRIFN-y on various immune functions, including NK cell activity, 
mitogen-induced blastogenesis and phagocytic activity of peritoneal exudate cells. 
Materials and methods 
Animals Male rats of the inbred LEW (RT11) strain were used. The animals were 12-
14 weeks of age, weighed 200-220 g and were bred under specific pathogen free 
conditions. 
IFN-y Recombinant DNA-derived rat IFN-y (rRIFN-y) was prepared from cultures 
of a transformed chinese hamster ovary cell line carrying the relevant gene encoding for 
RIFN-y. Details about the methods of production and purification have been described 
elsewhere (18). The rRIFN-y preparation used contained 2.5x106 laboratory reference 
units per mg protein and had a purity of more than 99%. The product was diluted in 
PBS at pH 7.8 and administered i.v. with a flow of 1.0 ml/hr. 
Bone marrow and blood cell countings One ml of heparinized blood was obtained from 
the tail vein to determine hemoglobin, red blood cell (RBC), white blood cell (WBC) 
and platelet (Pit) count. 
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Resection of both femoral bones was performed, each femur opened at the mid-shaft 
and the bone marrow obtained by flushing of the medulla with a fixed amount (2ml) of 
Hanks balanced salt solution (HBSS). Cells were counted using a Coulter counter. 
NK cytotoxicity assay Spleen lymphocytes were isolated by means of a Ficoll Isopaque 
density gradient, washed, resuspended in RPMI containing 10% fetal calf serum (FCS) 
and incubated for one hour at 37 • C in tissue culture flasks. Viability was assesed by 
means of trypan blue exclusion and was always more than 90%. Natural killer cytotoxicity 
was measured in round-bottem microtiter plates (Nunc, Denmark) in a 4-hr assay using 
51Cr labeled YAC target cells (19,20). Lymphocyte effector cells were added, in triplicate, 
at various concentrations according to the ratio of 25:1, 50:1, 100:1, and 200:1 respecti-
vely. To harvest cells, plates were centrifuged for one minute at 150 g and the superna-
tants were removed using the method described by Hirschberg (21). The release was 
determined by counting radioactivity in a gamma counter (LKB Wallace Ultragamma II). 
The maximum release was calculated by adding 10% cetavlon (ICI, UK) to an aliquot 
of target cells. Spontaneous release was defined as the 51Cr released from target cells 
incubated with medium alone. This value was usually 6-10% of the maximum. The 
percentage specific lysis was calculated according to the formula described by Reynolds 
(22). 
Mitogen stimulation assay Lymphocyte response to mitogen was tested using the 
phytohaemagglutination (PHA) and Concanavalin A (Con A) stimulation assay as descri-
bed by Kruisbeek (19). Spleen lymphocytes were adjusted to a concentration of 7.5 x 106 
cells per ml in RPMI 1640 medium enriched with 10% FCS. Cultures of 0.2 ml supple-
mented with 1 J.Lg PHA (Wellcome, UK) or 1 J.Lg Con A were maintained at 37 o C in a 
5% C02 humidified incubator for three days. Six hours before cells were harvested, 0.8 
JJ-Ci of methyl-3-H-thymidine eH-Tdr, specific activity 2CI/mmol; Amersham, UK) was 
added to each culture. Harvesting was performed using an automatic system (microtiter-
automash, Dynatech, Holland) collecting cells on fiber glass filters. Mter drying, the 
filters were placed in scintillation vials and 3 ml scintillation fluid was added. The uptake 
of 3H-Tdr (cpm) was determined with a liquid scintillation counter. Activity was ex-
pressed as stimulation index (SI) which was calculated by dividing the TdR uptake in 
stimulated cells by the uptake in non-stimulated cells. 
Phagocytic activity Peritoneal exudate cells (PEC) were obtained by injecting 25 ml 
of HBSS into the abdominal cavity, followed by gentle massage of the abdomen and 
aspiration of the peritoneal lavage. Viability of cells was checked by means of trypan 
blue exclusion. Formalinization and phagocytosis of sheep red blood cells (SRBC) was 
performed as described earlier (23,24). Briefly, 106 PECs resuspended in 2.5 ml RPMI 
supplemented with 10% FCS were plated in 35 mm plastic Petri dishes (Costar, USA) 
containing 24 mm square glass cover slips. The dishes were placed in a 5% C02 humidi-
fied incubator at 37 o C for 2 hours. Subsequently, the dishes were washed twice to 
remove nonadherent cells and incubated for one hour with 2.5 ml RPMI supplemented 
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with 10% FCS and containing 108 formaldehyde-treated SRBC. Mter this incubation 
period, the cover slips were rinsed with PBS and immediately fixed with 2.5% glutaral-
dehyde in 0.1 M cacodylate buffer at pH 7.4 for 10 min at 4 ·C. The cover slips were 
stained with hematoxylin and phagocytosis was quantified by counting the number of 
SRBC ingested per cell. The percentage of macrophages which contained one or more 
SRBC was determined (%phagocytosis) and by multiplying this percentage with the mean 
number of ingested SRBC a phagocytic index was calculated. 
Experimental design During a period of 48 consecutive hours rRIFN-y was adminis-
tered to LEW rats by continuous intravenous infusion at a dosage of 1.5 x lOS U /kg/hr. 
Continuous infusion was achieved by means of a catheter manipulated into the jugular 
vein and connected to an external compression pump. Rats were housed in metabolic 
cages and allowed to drink, eat and move freely during the long-term infusion. Since 
IFN-y induced effects are known to be executed relatively slowly, an interval of 12 hours 
was introduced between cessation of rRIFN-y treatment and assesment of immune 
functions. Controls were treated in a similar way, but received PBS adjusted at pH 7.8 
instead of rRIFN-y. Three series of identical experiments were performed. In the first 
series the experimental and control group consisted of 4 animals each; in the second and 
third series of 3 animals. Abdominal lavage, splenectomy and resection of the femoral 
bones was performed during one operation using ether anaesthesia. 
Statistics Data are presented as mean ± SEM unless otherwise stated. The results 
were analyzed using Student's t test A probabilty value smaller than 5% was taken as 
level of significance. 
Results 
Continuous infusion of rRIFN-y produced weight loss (8-12%) and weakness of all 
experimental animals. Marked changes in the number of peripheral blood and bone 
marrow cells were found (Table 4.1). When compared with controls, rRIFN-y treated 
rats displayed an impressive anemia, leukopenia and thrombocytopenia, accompanied by 
a reduction in the number of bone marrow cells. The number of spleen cells was equal 
in both groups. 
Assessment of NK cell response (Fig. 4.1) demonstrated that rRIFN-y treatment did 
lead to a significant enhancement of NK activity (p < 0.001). The increase of NK activity 
in the first series of experiments shown in Fig. 4.1 is representative for the results 
obtained in the second and third series. Enhancement of NK activity was found in all 
rRIFN-y treated rats. 
The response of spleen cells from rRIFN-y treated rats to mitogen stimulation is shown 
in Table 4.2. A significant increase (p < 0.05) of the stimulation index of the experimental 
group was observed and found to be more than twice as large as the control value. 
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Table 4.1. Effect of rRIFN-y on Hb and the number peripheral blood-, bone marrow- and spleen cells. 
rRIFN-y Controls p 
Hb (mmol/L) 4.4 ± 1.3 8.0 ± 0.6 <0.005 
RBC (x 1o'2/L) 3.0 ± 0.3 5.9 ± 0.2 <0.005 
WBC (x 109 /L) 3.8 ± 1.3 9.7 ± 1.6 <0.005 
Plt (x 1012/L) 75.6 ± 10.7 300.0 ± 68.5 <0.005 
BM (x 109 /L) 4.5 ± 0.4 10.4 ± 0.7 <0.005 
Spleen (x 109 /L) 11.1 ± 1.5 9.4 ± 2.5 
rRIFN-y was given by continuous i.v. infusion for 2 days (n=4). Controls were given PBS (n=4). 
Hb: hemoglobin; RBC: red blood cells; WBC: white blood cells; Plt: platelets; BM: bone marrow. 
Table 4.2. Effect of rRIFN-y on mitogen-induced blastogenesis of spleen cells 
Mitogen rRIFN-y PBS p 
Con A 126.0 ± 27.5 44.4 ± 10.0 <0.05 
PHA 57.7 ± 12.1 19.0 ± 4.0 <0.05 
rRIFN-y was given by continuous i.v. infusion for two days; controls were given PBS. 
Each group consisted of 3 animals. Data represent stimulation index ± SEM. 
The effect of rRIFN-y treatment on the phagocytic capacity of peritoneal exudate cells 
is shown in Table 4.3. Although phagocytosis by PEC of some rRIFN-y treated rats was 
quite impressive, there was no significant difference between the number of SRBC 
ingested per cell in the experimental and control group. In the second and third series 
of experiments one out of three rRIFN-y treated rats was found to have PEC that 
ingested more than twice the number of SRBC per PEC when compared with controls. 
The results found in other experimental animals, however, were not different from the 
controls. In the second and third series of experiments, the percentage of cells involved 
in phagocytosis appeared to be significantly higher in rRIFN-y treated rats. All PECs 
from these animals were found to execute phagocytic activity. The phagocytic index of 
peritoneal cells obtained from rRIFN-y treated animals was significantly enhanced in the 
second and third series of experiments. 
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Table 4.3. Effect of rRIFN-y on phagocytosis of SRBC by peritoneal exudate cells (PEC). 
PEC/ml %phagocytosis SRBC/cell PI p 
rRIFN-y 3.0 ± 1.0 92.5 ± 7.5 9.8 ± 0.7 906 
<0.05 
PBS 2.3 ± 0.9 84.7 ± 2.3 7.1 ± 1.1 601 
rRIFN-y nd 100.0 ± 0.0 22.2 ± 7.8 2220 
<0.001 
PBS nd 78.7 ± 1.3 8.9 ± 0.3 700 
rRIFN-y 4.3 ± 2.3 100.0 ± 0.0 18.4 ± 6.7 1840 
<0.001 
PBS 3.9 ± 0.5 68.0 ± 3.2 10.0 ± 1.8 680 
rRIFN-y was given by continuous infusion for 2 days; controls were given PBS. PEC/ml: 
number of peritoneal exudate cells/ml harvested after i.p. injection of 25 ml HBSS.% phago-
cytosis:% of PEC involved in phagocytosis ± SD; SRBCjcell: mean ± SD of SRBC ingested 
per PEC. PI: phagocytic index, number of ingested SRBC per 100 PEC. The experiments were 
performed in triplicate; each group consisted of 3-4 animals. 
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Figure 4.1. Enhancement of NK cell activity of spleen lymphocytes after rRIFN-y treatment. rRIFN-y was 
given by continuous i.v. infusion at a dosage of 1.5 x !OS U /kg/hr for two consecutive days. Controls received 
PBS. The percentage of specific lysis is shown as determined in a 4hr 51Cr release assay. A significant 
difference in NK cell activity is found between rRIFN-y and PBS treated animals at all indicated effector 
to target cell ratios (p<0.001). 
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Discussion 
The results presented in this study demonstrate conclusively that rRIFN-y has immuno-
modulatory properties in vivo. Our findings in the rat model are in agreement with those 
of mouse and human studies investigating the effects of recombinant mouse and human 
IFN-y, respectively (1-9). However, most of these studies were performed in vitro and 
few experimental models have been presented so far that are representative for the 
biologic activities of IFN-y in vivo (25). 
All animals that were treated with rRIFN-y displayed a marked reduction in body 
weight, up to 12% in 2 days, and were in a bad condition. It is well known from human 
studies that treatment with IFN-y may induce flu-like symptoms, including fever, 
shivering and gastro-intestinal distress leading to nausea and loss of appetite. These toxic 
side-effects may well explain the observed changes in the experimental animals. 
When compared with treatment schedules used in clinical studies (26), it must be noted 
that a very high dosage of rRIFN-y was given. This dosage was administered by conti-
nuous infusion to obtain high serum levels of rRIFN-y, up to 200 Vjml (P.H. van der 
Meide, personal communication). Earlier, we demonstrated that rRIFN-y given by single 
i.v. injections was rapidly removed from the circulation and induced no changes in NK 
cell activity, phagocytosis and mitogen-induced blastogenesis (27). In physiologic con-
ditions, no serum levels of IFN-y can be detected systemically, not even with very 
sensitive biologic assays. However, locally at the intercellular level, high concentrations 
of IFN-y may be present, since lymphocytes will release IFN-y directly into their 
pericellular environment. Most recently, it has been reported that T cells may even direct 
their lymphokine secretory apparatus towards the site of the cell part that is stimulated 
(28,29). Thus, very high concentrations ofiFN-y may be produced exactly at the location 
needed. By cell binding, dilution into plasma and renal filtration, IFN-y will be cleared 
and the serum concentration will be very low. Considering the toxicity of exogenous ad-
ministered IFN-y, the rapid physiologic clearance may be directed to protect the 
organism against adverse effects of its own products. 
Examination of peripheral blood cells showed a marked pancytopenia in all rRIFN-y 
treated rats. Similar hematologic changes have been described in clinical phase I studies 
investigating the toxicity of recombinant human IFN-y (30,31). Direct cytolysis may well 
be responsible for this effect as blood cells were continuously exposed to high levels of 
IFN-y (10,11). Reduction of the number of bone marrow cells may be caused by the 
same mechanism. Recently, Steiniger reported a significant increase of myelo-monocytic 
cells in the peripheral blood after IFN-y treatment (32). Although some increase of 
younger cells in differential white blood cell counts was noted, we did not observe an 
increase of myelo-monocytic cells. 
In this study, it is demonstrated for the first time that rRIFN-y may induce a significant 
enhancement of NK cell activity in vivo. This finding offers new perspectives to study the 
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relevance of the NK-IFN system in immune surveillance against tumors (33). It has been 
suggested that absence of NK cell activity is associated with increased incidence of spon-
taneous and experimental metastasis of several tumors (34,35). With the availability of 
the model used in the current experiments, new studies can be designed to determine the 
effect of enhanced NK cell activity on the process of carcinogenesis and metastasis. 
Weigent (36) reported that IFN-y had a 50-fold greater ability to enhance NK-activity 
in human lymphocytes than IFN-ajB. Earlier, we found a stimulating effect of IFN-a on 
NK cell activity in the rat model. However, a comparison with the potency of rRIFN-y 
can not be made, since partially purified IFN-a preparations were used. 
IFN-y is known to exert pleiotropic effects on mature macrophages (8,37). Activation 
of macrophages is thought to be one of the major physiologic functions of IFN-y. In the 
present study, rRIFN-y treatment was found to increase phagocytosis by peritoneal 
exudate cells significantly. It can be assumed that IFN-y, released during infectious dis-
eases, stimulates phagocytic cells to enhanced activity, leading to the removal of foreign 
material. Several experimental studies have shown that IFN-y has the capacity to alter 
the course of microbial infections (38,39). Hershman found that IFN-y treatment in a 
murine bum wound model reduced mortality after bacterial challenge (39). Since severe 
bum wounds may cause depression of immune functions (40), IFN-y therapy may be of 
importance in these cases to activate the immune system. 
rRIFN-y treatment was found to enhance mitogen-indfi;ced blastogenesis of T cells. 
This finding suggests that IFN-y is involved in the induction of nonspecific enhancement 
of host T cell defense mechanisms. Gromo and co-workers demonstrated that the addi-
tion of IFN-y to activated T cells led to the acquisition of cytotoxicity by CDS T cells in 
vitro (2). As demonstrated in this study, rRIFN-y enhanced the activity of NK cells, 
macrophages and T lymphocytes, all of which are able to destroy tumor cells, at least in 
vitro ( 41,42). Recently, we reported on the efficacy of rRIFN -y on a weakly immunogenic 
adenocarcinoma of the colon in a liver metastasis model ( 43). While in vitro no direct 
antiproliferative effect of rRIFN-y was found, a reduction of the number of liver meta-
stases was observed in rRIFN-y treated rats. This finding suggests that indirect 
mechanisms, such as rRIFN-y induced immune responses, are responsible for the anti-
tumor effect. The results presented in the current study are in agreement with this 
hypothesis. 
In the last decade much experimental and clinical research has been focused on the 
impact of anaesthesia, surgery and blood transfusions on the immune system. Depression 
of immune functions by these procedures have been reported (44-47). Considering the 
immunostimulating effects of rRIFN-y presented in this study, IFN-y treatment may 
offer new perspectives to modulate immune functions perioperatively. 
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Chapter 5 
INDUCTION OF MHC CLASS II ANTIGENS BY rRIFN-y IN VIVO 
Abstract 
In this chapter the expression of MHC class II antigens is studied in different organs 
of various rat strains after treatment with rRIFN-y. The recombinant lymphokine was 
administered intravenously by continuous infusion during 36 hours. MHC class II 
antigens were demonstrated with a monoclonal antibody (OX-6) and immuno-
peroxidase staining. All organs studied showed increased expression of MHC class II 
antigens after treatment with rRIFN-y. Differences in the pattern of expression were 
found on vascular endothelial cells. MHC class II antigen expression was induced on 
endothelial cells of larger vessels in different organs of LEW rats, but not on 
endothelial cells of BN and WAG rats. Changes in the pattern of MHC class II 
expression in different organs are described in detail. 
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Introduction 
Cell membrane molecules encoded by genes of the MHC play an important role in 
immune responses. T cells recognize antigen presented in complex with MHC 
molecules on the cell membrane of antigen-presenting cells (1). Allogeneic MHC 
molecules have been demonstrated to be highly immunogenic in transplantation 
responses. 
The expression of MHC antigens on the cell membrane is regulated by cytokines. 
MHC antigen expression is increased or induced de novo by IFN-y (2,3), a cytokine 
predominantly produced by activated T lymphocytes ( 4,5). It is well established that 
IFN-y has pleiotropic effects on cells involved in immune reactions (6). Based upon 
in vitro studies, the capacity of IFN-y to induce the expression of MHC class ll anti-
gens is thought to be one of its main functions. In autoimmune and alloimmune 
reactions de novo induction of MHC class ll antigens can be observed on cells that 
normally do not express class ll antigens. It is speculated that cells expressing de novo 
MHC class ll antigens may function as APC and reinforce ongoing immune 
responses. However, the relevance of de novo induction of MHC class ll antigens in 
vivo remains to be determined. 
With the production of recombinant IFN-y for the rat species, a new model has 
become available to study the importance of MHC class ll antigen expression in vivo. 
The present study was initiated to investigate the effect of recombinant rat IFN-y on 
MHC class II antigen expression in different organs of various rat strains. 
Materials and methods 
Animals Male inbred BN (RT1°) rats, WAG (RTlu) rats and LEW (RT11) rats 
were used. The animals were bred under specific pathogen-free conditions, weighed 
200-250 g, and were 10-12 weeks old. 
rRIFN-y Recombinant DNA-derived rat interferon-gamma (rRIFN-y) was prepar-
ed from cultures of a transformed chinese hamster ovary cell line carrying the 
relevant gene encoding for rat IFN-y. Details about the methods of production and 
purification have been described elsewhere (7). The rRIFN-y preparation used, 
contained 2.5 x 106 laboratory reference units per mg protein. The product was 
diluted in PBS at pH 7.8 and administered at a flow of LO ml/hr. 
Immunoperoxidase staining After removal, organs were embedded in Tissue Tek 
(Miles Laboratories, Naperville, USA), snap-frozen in liquid nitrogen, and cut in 5 
J.Lm sections using a cryostat microtome (Bright Instrument Comp, Huntingdon, 
England) at -20 ° C. Frozen sections were mounted on to glass slides, allowed to air 
dry for six hr, fixed in acetone for 10 min and washed 3 times in PBS. Subsequently, 
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the sections were exposed for 45 min at room temperature in a humidified atmosphe-
re to OX-6 (Flow Laboratories, England), a monoclonal antibody directed against 
MHC class II antigens. Peroxidase-conjugated rabbit anti-mouse immunoglobulin (No-
rdic, The Netherlands) was used as secondary step. Diaminobenzidine was used as 
chromogen. After each step the sections were washed 3 times in PBS. Finally, they 
were mounted in malinol. 
Luconyl staining Luconyl blue (No 708, BASF, FRG) is a dye consisting of 
macromolecules unable to pass the vascular endothelial lining. When injected 
intravenously, Luconyl blue remains in the vascular system and therefore can be used 
to identify vessels of any caliber in histological sections. Luconyl blue was kindly 
provided by Dr. Reinhold (TNO, Rijswijk, The Netherlands). The dye was diluted 4:6 
in PBS and injected i.v. at a dose of 1.5 mljrat. 
Experimental design rRIFN-y was given to LEW (n=4), BN (n=3), and WAG 
(n=3) rats at a dosage that induces class II antigen expression on endothelial cells of 
LEW rats, as was demonstrated in a pilot study. rRIFN-y was administered by con-
tinuous intravenous infusion at dosages of 1.5 x lOS U /kg/hr during a period of 36 
consecutive hr. Intravenous infusion was achieved by means of a catheter introduced 
into the jugular vein. The catheter was connected to an external compression pump 
(Perfusor, Braun, FRG). Rats were housed in special cages provided with a system to 
protect the catheter, but allowing free movement and intake of water and food. Of 
each strain two animals were used as controls; they were treated with PBS at the 
same pH (7.8) and flow-rate (lml/hr) as the experimental animals. Twelve hours 
after cessation of rRIFN-y treatment, the animals were killed and their organs 
removed for immunohistological staining. One animal of each experimental group was 
injected with Luconyl blue, 5 min before sacrifice, to enable identification of small 
vascular structures, such as capillaries. Heart, kidney, liver, pancreas, spleen, colon, 
and skin were examined for MHC class II antigen expression. 
Results 
Analysis of MHC class II antigen expression after rRIFN-y treatment showed an 
increase of class II antigen positive cells in different organs of all strains (Table 5.1). 
Induction of MHC class II antigen expression was mainly observed on non-parenchy-
mal interstitial cells. The pattern of MHC class II antigen expression on cells of heart, 
kidney, liver and pancreas of LEW rats after rRIFN-y treatment is summarized in 
Table 5.2. Compared with BN and WAG rats, a different pattern of MHC class II 
antigen expression was found on endothelium of large vessels of LEW rats. Normally, 
vascular endothelial cells of BN, LEW, and WAG rats do not express MHC class II 
antigens. After treatment with rRIFN-y, MHC class II antigen expression was found 
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on vascular endothelial cells of different organs of LEW rats. The same dosage of 
rRIFN-y did not induce de novo induction of MHC class ll antigen expression on 
vascular endothelium of BN and WAG rats. 
Table 5.1. Induction of MHC class II antigen expression after rRIFN-y treatment on interstitial and en-
dothelial cells of LEW, WAG and BN rats. 
Interstitial cells• 
Endothelium of large vessels 
Endothelium of capillaries 
control 
+ 
a) interstitial cells having a dendritic-like appearance 
rRIFN-y 
++ 
+b 
b) in LEW but not in BN or WAG rats; rRIFN-y was administered at a dose of 1.5 x lo' U/kg/hr 
during a period of 36 hours 
Except for the difference in expression of MHC class ll antigens on vascular 
endothelium between LEW rats and BN/WAG rats, the pattern of induction in dif-
ferent organs and strains showed great resemblance. An increase in the number of 
MHC class ll positive dendritic-like cells was a major finding in all organs of different 
strains. 
In hearts of rRIFN-y treated animals an increase in the number of MHC class ll 
positive interstitial cells was observed. Class ll positive interstitial cells were equally 
distributed among myocardial cells that remained class ll negative. De novo induction 
of class ll antigen expression was observed on endothelium of large vessels and 
endocardium of LEW rats, but not on endothelium of BN or WAG rats. Endothelial 
cells of capillaries did not express class ll antigens in any strain. 
In kidneys of control rats class ll antigen expression was found on interstitial cells, 
mainly located in the cortical part and in glomeruli, and on epithelial cells of proxi-
mal convoluted tubules (Fig. 5.1). MHC class ll antigen expression was not observed 
on any other renal structure. Epithelial cells of the proximal convoluted tubules of 
BN rats showed stronger class II antigen expression than those of WAG and LEW 
rats. In BN rats, the change in MHC class II antigen expression could even be seen 
macroscopically in the cortex. On microscopic examination, an increase in the number 
of class ll positive cells was found in the cortical interstitium and in glomeruli. 
rRIFN-y induced class II antigen expression on the parietal layer of Bowman's cap-
sule surrounding the glomerular structures. A strong class ll antigen induction was 
found on proximal convoluted tubular cells; the distal convoluted cells only stained 
faintly. Within the medullary zone weak class II expression was found on Henle's loop 
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and, more strongly, on collecting tubules. Vascular endothelial cells of arteries 
expressed MHC class II antigens, whereas cells of capillaries and veins did not. 
Table 5.2. MHC class II antigen expression after rRIFN-y treatment of LEW rats. 
Organ Cell type Control rRIFN-y 
-
Heart myocytes 
endocardium - + 
Kidney glomeruli 
-Bowman's capsule - + 
- interstitial cells + ++ 
prox. convoluted tubules + ++ 
prox. straight tubules 
Henle's loop - ± 
dist. straight tubule - ± 
dist. convoluted tubules - ± 
collecting tubules - ± 
Liver hepatocytes 
bile ducts - ± 
Kuppfer cells - + 
Pancreas exocrine acinar cells - ± 
endocrine islet cells 
epithelial duct cells - + 
rRIFN-y was administered at a dose of 1.5 x lOS U /kg/hr during a period of 36 hours 
In a normal liver (BN, LEW or WAG) interstitial dendritic-like cells are the only 
structures expressing class II antigens. The distribution of these cells is mainly restric-
ted to the portal triads. After rRIFN-y treatment an increase in th
1
e number of these 
cells was observed in all strains (Fig. 5.2). In addition, class II antigen expression was 
found on epithelial bile duct cells and on endothelium of arteries of LEW rats. MHC 
class II expression was not ,found on endothelial cells of central or portal veins. 
Hepatocytes did not express class II antigens either. 
In control animals the only class II positive structures in pancreas are dendritic-like 
interstitial cells. rRIFN-y increased the number of class II positive interstitial cells 
markedly in all rat strains. A strong induction of class II antigen expression was found 
on acinar cells, epithelial pancreatic duct cells and vascular endothelial cells of large 
arteries and veins of LEW rats (Fig. 5.3). In none of the strains class II antigen 
expression was found on pancreatic islet cells or on capillary cells. 
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In spleens of control animals class II positive cells are mainly present in the 
marginal zone, in follicles and in the red pulp. After treatment with rRIFN-y an 
increase in the number of class II positive cells was found in the red pulp. In addition, 
induction of class II expression was found on the vascular endothelium of the central 
arteries of LEW rats. 
In the colon of control animals dendritic-like class II positive cells can be found in 
the lamina propria. Enterocytes normally do not express class II antigens. After 
treatment with rRIFN-y a strong increase in the number of dendritic-like class II 
positive cells was observed in the lamina propria. In contrast to liver and heart 
parenchymal cells, colon enterocytes strongly expressed class II antigens after rRIFN-
Y treatment in all rat strains. As observed in all other organs, vascular endothelium of 
large arteries were induced to express class II antigens in LEW rats, but not in WAG 
or BN rats. 
In skin biopsies of normal rats class II antigen expression is found on dendritic-like 
cells that are mainly located in the dermal layer and, rarely, in the basal layer of the 
epidermis. After treatment with rRIFN-y the number of class II positive cells was 
strongly increased in the dermal layer as well as in the basal layer of the epidermis. 
Again, the vascular endothelium of arteries expressed class II antigens in LEW rats, 
but not WAG or BN rats. 
The toxicity of rRIFN-y treatment differed markedly between various strains. BN 
rats treated with rRIFN-y remained in a fairly good condition. In contrast, the 
condition of WAG and LEW rats treated with rRIFN-y deteriorated and most of 
these animals became severly cachectic. A weight loss of 20% was noted for 
experimental animals compared with 5% for control animals. One LEW rat died 
during rRIFN-y treatment at the second day. At autopsy pleural and peritoneal 
exudate was found. Microscopic examination of HE sections showed multiple small 
infarctions of liver, spleen and kidneys. Pleural exudate cultures showed bacterial 
growth. 
Discussion 
In this study it is clearly demonstrated that continuous infusion of rRIFN-y induces de 
novo class II antigen expression in different rat organs. This finding confirms earlier 
reports by Steiniger et al. (8). The pattern of class II antigen expression was found to 
be highly reproducible. Interestingly, cell types of common origin but located in 
different organs, such as epithelial or endothelial cells, reacted with the same pattern 
of expression. Epithelial cells, such as bile duct cells, keratinocytes and enterocytes, 
reacted most strongly to rRIFN-y treatment. The induction on vascular endothelial 
cells of large vessels was only observed in one strain and appeared to be less intense, 
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although consistently present. In none of the strains studied cell types, such as 
capillaries and parenchymal cells of heart, liver and endocrine islet cells did show any 
response to rRIFN-y treatment. 
As mentioned above, the pattern of class II induction varied between different 
strains with respect to class II induction on endothelial cells of large vessels. Using 
the same dose of rRIFN-y, de novo induction of class II antigen induction was 
observed on vascular endothelium of organs of LEW rats, but not of BN or WAG 
rats. We did not determine serum levels of rRIFN-y to investigate the pharmaco-
dynamics of rRIFN-y. It might be argued that the process of elimination of rRIFN-y 
by clearance or inactivation differs between distinct rat strains. Thus, if LEW rats 
have a lower clearance rate of rRIFN-y than the other rat strains, LEW rats might 
have had higher serum concentrations of the lymphokine. To support this hypothesis 
it can be argued that rRIFN-y induced only minor toxic effects in BN rats, while it 
induced markedly more toxicity in LEW rats. However, WAG rats suffered from 
rRIFN-y toxicity to the same degree as LEW rats, but had no class II induction on 
the vascular endothelium. In addition, the changes in the number of class II positive 
dendritic-like cells strongly suggest that the serum concentrations of rRIFN-y 
achieved in BN and WAG rats were sufficient to induce class II antigen expression. 
More likely, it can be assumed that there is a genetic difference in the potency of 
endothelial cells of distinct strains to express class II antigens. In addition, the affinity 
of receptors for IFN-y may vary between cell types (9) and in some cells it has been 
demonstrated that a combination of mediators may be necessary to induce class II 
expression (10). 
It is well established that the outcome of transplantation experiments varies with rat 
strain combinations. Graft immunogenicity is determined significantly by MHC 
incompatibility and the degree of mismatch will affect the immune response of the 
host. It will be of interest to investigate whether different patterns of class II antigen 
expression on dendritic-like interstitial cells and/ or vascular endothelial cells of a 
graft influence its immunogenicity and thereby graft rejection. Thus, differences in the 
outcome of transplantation experiments could be explained. 
In this study it has been demonstrated that rRIFN-y may induce different patterns 
of class II antigen expression in distinct rat strains. If rRIFN-y treatment is used to 
induce class II antigen expression prior to transplantation experiments, attractive 
models become available to investigate the importance of class II antigen expression 
on different structures to the process of graft rejection. 
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Figure 5.1. 
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Photomicrograph showing MHC class II antigen expression on renal structures of PBS 
(a) and rRIFN-y (b) treated LEW rats after immunoperoxidase staining using 
monoclonal antibody OX-6. x 200. 
Figure 5.2. Photomicrograph showing MHC class II antigen expression on hepatic structures of 
PBS (a) and rRIFN-y (b) treated LEW rats after immunoperoxidase staining using 
monoclonal antibody OX-6. x 90. 
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Figure 5.3. 
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* 
'it 
~- a 
Photomicrograph showing MHC class II antigen expression on pancreatic structures of 
PBS (a) and rRIFN-y (b) treated LEW rats after immunoperoxidase staining using 
monoclonal antibody OX-6. x 120. 
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Chapter 6 
TREATMENT WITH rRIFN-y HAS NO 
EFFECT ON CARDIAC ALLOGRAFT REJECTION 
Abstract 
The effect of rRIFN-y on allograft rejection was studied in BN (RT1n) to WAG 
(RT1u) and BN to LEW (RT11) rat heart transplantation models. Recipients were 
treated with rRIFN-y by intraperitoneal or intravenous injection, either by bolus or 
continuous infusion. Treatment was started immediately after transplantation and 
continued during a period ranging from 4 to 10 days; dosages varied from 2.5 x 102 
U/kg/day to 3 x 106 U/kg/day. Controls received PBS. 
Treatment with rRIFN-y had no effect on allograft survival, irrespective of. the 
route of administration, the dosage used and the duration of treatment. Higher 
dosages of rRIFN-y were found to be toxic with a mortality rate up to 75%. LEW 
rats were found to be more sensitive than WAG rats. 
This chapter is being published in a modified form in Immunology (in press) 
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Introduction 
IFN-y has the capacity to modulate several aspects of the immune response (1,2). It 
has been demonstrated that IFN-y is involved in the activation of macrophages (3,4), 
and natural killer cells (4,5), differentiation of T-cells and acquisition of cytotoxicity 
by CDS T-cells (6,7) as well as differentiation of B-cells into immunoglobulin-
secreting plasma cells (8). In addition, IFN-y induces enhanced expression of cell 
membrane molecules, including antigens encoded by genes of the MHC (1,2). As 
demonstrated in vitro, all of these mechanisms may be involved in immune responses 
that eventually lead to the rejection of an allograft (9,10). Thus, IFN-y, released by 
activated T cells upon allogeneic stimulation, may play a pivotal immunoregulatory 
role in the rejection process. 
Immunomodulating effects of riFN-y within the rat model have been demonstrated 
previously (11). In the present experiments the effect of rRIFN-y on the process of 
graft rejection was studied in a rat heart transplantation modeL 
Materials and methods 
Animals Male inbred BN rats (RT1n), WAG rats (RTlu) and LEW rats (RT11) 
were used. The animals were bred under specific pathogen free conditions, weighed 
200-250 g, and were 10-12 weeks old. 
IFN-y Recombinant DNA-derived rat interferon-gamma (rRIFN-y) was prepared 
from cultures of a transformed chinese hamster ovary cell line carrying the relevant 
gene encoding for rat IFN-y. Details about the methods of production and purifica-
tion have been described elsewhere (12). The IFN-y preparation used, contained 2.5 x 
106 laboratory reference units per mg protein. Dilutions were made in PBS at pH 7.8. 
Heart transplantation Heterotopic heart transplantations were performed as 
described previously (13). Cessation of heart beat was taken as moment of graft 
rejection. 
Experimental design After cardiac transplantation, rRIFN-y treatment of recipients 
was started. Different routes of rRIFN-y administration were selected, including i.p. 
and i.v. injection, either by bolus or continuous infusion. Group I and IX were 
designed to establish the moment of graft rejection in the unmodified BN to WAG 
and BN to LEW combination, respectively. In addition, the following experiments 
were performed: 1) daily treatment of WAG recipients with rRIFN-y by i.v. bolus 
injection at a dosage of 1.5 x 104 U /kg (group III) and 2.5 x lOS U /kg (group IV) 
during 7 consecutive days; 2) treatment of WAG recipients with rRIFN-y, 3 times 
daily i.p. at a dosage of 106 U /kg, during 4 (group V) or 10 consecutive days (group 
VII); 3) treatment of LEW recipients with rRlFN-y, once daily i.p. at a dosage of 2.5 
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x lOS U /kg during 4 consecutive days (group XI) or 3 times daily i.p. at a dosage of 
106 U /kg during 4 days (group XII) 3) treatment of lEW recipients with rRIFN-y by 
means of continuous i.v. infusion at a dosage of 104 U /kg/hr (group XIV) or 5 x 104 
U /kg/hr (group XV) during 4 days. Controls (group II, VI, VIII, X, and XIII) were 
treated with PBS adjusted at pH 7.8. Continuous i.v. infusion was achieved by a 
catheter introduced into the jugular vein and connected to an external compression 
pump (PerfusorR, Braun, Melsungen, FRG). 
Statistics Wilcoxon rank-sum test was used to determine differences in survival 
times of cardiac grafts. P-values smaller than 0.05 were considered statistically 
significant. 
Results 
Toxicity of rRIFN- y treatment 
In the first series of experiments, in which rRIFN-y was injected i.v. daily in low 
dosages, no signs of toxicity were found (Table 6.1). In the other series, in which 
higher dosages of rRIFN-y were administered, either by i.p. or continuous i.v. 
injection, treatment was associated with high morbidity and mortality. In these 
experiments, rRIFN-y treated animals were in a bad condition and showed reduction 
of body weight. LEW rats appeared to be more sensitive to rRIFN-y toxicity than 
WAG rats. All WAG rats treated i.p. with rRIFN-y at a dosage of 3 x 106 U/kgjday 
during 4 days survived (Table 6.2, group VI), whereas prolongation of rRIFN-y 
treatment to a period of 10 days resulted in a mortality of 37% (Table 6.2, group 
VIII). In the BN-LEW combination i.p. treatment with rRIFN-y at dosages of 3 x 106 
U/kg/day during 4 days led to a mortality of 45% (Table 6.3, group XIII). When the 
dosage of rRIFN-y was reduced twelvefold to 2.5 x lOS U /kg (Table 6.3, group XII) 
all LEW recipients survived. 
Administration of rRIFN-y by continuous i.v. infusion did not reduce morbidity or 
mortality, although serum peak levels were avoided by this technique. On the 
contrary, 43% of LEW recipients treated with 104 U/kg/hr and 75% of those treated 
with 5 x 104 U/kg/hr died (Table 6.4). Pleural and peritoneal exudates were the main 
findings at autopsy. 
Effect on graft survival 
In the unmodified BN-WAG combination, grafts were rejected in 8-9 days (Table 1.1, 
group I). Treatment with rRIFN-y led to shortening as well as prolongation of graft 
survival, but none of these changes was found to be of significance when compared 
with controls. Treatment of WAG recipients with rRIFN-y at a dosage of 3 x 106 
U /kg/ day did lead to allograft survival times ranging from 6-13 days compared to 
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Table 6.1. Survival of BN hearts transplanted to WAG recipients treated i.v. with rRIFN-y. 
group n treatment days survival time 
I 9 none - 8 (8x), 9 
n 6 PBS 7 8,8,8,8,9,9 
III 7 rRIFN-y 7 8,8,8,8,8,9,9 
1.5x1<fU /kg 
IV 7 rRIFN-y 7 8,8,8,9,9,9,10 
2.5x10SU fkg 
WAG rats were treated i.v. with rRIFN-y for 7 consecutive days; treatment was started at the day of 
transplantation. 
Table 6.2. Survival of BN hearts transplanted to WAG recipients treated i.p. with rRIFN-y. 
group n treatment days survival time 
v 11 rRIFN-y 4 6,6,6,7,7,8,9,11,11,11,13 
VI 6 PBS 4 7,7,8,8,9,9 
VII 8 rRIFN-y 10 4,9,12,15,16 [7,10,10] 
VIII 6 PBS 10 9,9,10,10,11,12 
WAG rats were treated ip. with rRIFN-y at a dosage of 3 x 106 U/kg/day; treatment was started at the 
day of transplantation. [ ] recipients died with functioning graft 
controls showing a range from 7-9 days (Table 6.2. group VI vs. VII; p>0.05). 
Extension of rRIFN-y treatment to 10 days resulted in graft survival times from 4-16 
days (group VIII), not significantly different from survival times of PBS treated 
controls (9-12 days, group IX; p > 0.05). 
Treatment of LEW recipients with rRIFN-y, either i.p. (Table 6.3) or i.v. by conti-
nuous infusion (Table 6.4), had no significant effect on graft survival. A dose-response 
effect was found for rRIFN-y toxicity (group XV vs XVI). Interestingly, it was 
observed that the method of drug administration, i.e. continuous infusion, had a small 
though significant effect on graft survival. Recipients treated with PBS by continuous 
infusion showed graft survival times that were prolonged compared to those of 
recipients treated with PBS i.p. (group XIV: 11.2 ± 1.5 days vs group XI: 7.4 ± 0.6, 
p<0.035). 
70 
Table 6.3. Survival of BN cardiac grafts in LEW recipients treated i.p. with rRIFN-y. 
group n treatment 
IX 10 none 
X 14 PBS 
XI 8 rRIFN-y 
2.5x10SU /kg/ day 
XII 11 rRIFN-y 
3.0x10~ /kg/ day 
rRIFN-y treatment was started at the day of transplantation. 
[ ] recipients died with functioning graft 
days survival time 
6(5x), 7(5x) 
4 7(10x),8(3x),9 
4 7,7,8,8,9,9,14,15 
4 6, 7, 7,11,11,13 
[4,4,5,6,7) 
Table 6.4. Survival of BN cardiac grafts in LEW recipients treated i.v. with rRIFN-y. 
group n treatment days survival time 
XIII 6 PBS 4 9,10,11,12,12,13 
XIV 7 rRIFN-y 4 5,7,12,19 [2,8,11] 
1x104U /kg/hr 
XV 8 rRIFN-y 4 11,13 [ 1,2,2,2,8,8] 
5x104U jkg/hr 
rRIFN-y was given by continuous infusion starting immediately after transplantation. 
[ ] recipients died with functioning graft 
Discussion 
In the current study it was demonstrated that systemic treatment of graft recipients 
with rRIFN-y has no effect on the outcome of the rejection process. Although various 
dosages, routes of administration and treatment periods were tested in different strain 
combinations, none of the treatment schedules revealed a significant effect of rRIFN-
Y treatment on graft rejection. 
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Most recently, Paineau reported on the effects of rRIFN-y on allograft rejection 
(14). He studied the effect of low dosages of rRIFN-y (lOS U/kg/day) in combination 
with blood transfusions. No effect on the survival of heart allografts was found if 
rRIFN-y treatment was given alone. However, when recipients were transfused with 
donor strain blood, leading to a slight but significant prolongation of graft survival, 
rRIFN-y treatment resulted in further prolongation. The author concluded that IFN-y 
might have an immunosuppressive rather than immunostimulatory effect. If anything, 
the results from Paineau's and our study suggest that IFN-y alone does not have the 
potency to activate the immune system. This concept may be supported by data re-
ported by Billiau (15). This investigator found that IFN-y alone is not able to increase 
the inflammatory process in mice, whereas antibodies directed against IFN-y are able 
to inhibit it, indicating the involvement IFN-y in inflammation. However, the effect of 
anti-IFN-y treatment may depend on the experimental model used. In rat and mon-
key transplantation studies treatment with anti-IFN-y serum and monoclonal anti-
bodies, respectively, did not lead to changes in allograft survival (16,17). The findings 
of these studies and the present one indicate that positive or negative interference 
with the actions of IFN-y alone is ineffective to manipulate allograft rejection. 
High dosages of rRIFN-y led to serious toxicity and even mortality with marked 
differences between various rat strains. Administration of rRIFN-y by continuous 
intravenous infusion to avoid serum peak levels did not reduce morbidity and mor-
tality. The use of high dosages of rRIFN-y can therefore be excluded as a means to 
manipulate the process of rejection. 
It was found that prolonged handling of graft recipients as such prolonged graft 
survival, irrespective of the drug administered. This finding stresses the importance of 
appropriate controls if minor effects of an experimental treatment are anticipated. 
In conclusion, systemic treatment of allografted rats with rRIFN-y in low and mode-
rate dosages has no effect on graft survival; high dosages of rRIFN-y are associated 
with severe toxic side-effects impeding possible immunoregulation by rRIFN-y at 
these concentrations. 
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Chapter 7 
INCREASE OF MHC CLASS II POSITIVE CELLS IN CARDIAC 
ALLOGRAFTS BY rRIFN-y HAS NO IMPACT ON GRAFT SURVIVAL 
Abstract 
The present study was initiated to investigate the efficacy of donor pretreatment with 
IFN-y to induce MHC class II expression in heart tissue, and to investigate whether 
this pretreatment would influence heart allograft survival. BN rats were used as 
donors and RT-1 incompatible LEW rats as recipients. During a period of 3 consecut-
ive days prior to transplantation, rRIFN-y was administered to BN rats via continuous 
i.v. infusion at dosages of 103, 104 and 5x104 U /hr. Control rats received PBS; each 
group consisted of 9 rats. Analysis of rRIFN-y induced MHC class II expression by 
immunoperoxidase staining revealed a significant, fourfold increase of the number of 
dendritic-like cells, irrespective of the rRIFN-y dose given (controls: 15±4 vs. highest 
dose group: 57± 9 cells/mm2; p < 0.005). Endothelial cells of arteries and venules 
remained MHC class II negative. Grafting of hearts of rRIFN-y perfused donors 
resulted in the same survival time as compared to controls. These results indicate that 
upgrading of MHC class II antigen expression on dendritic-like cells is not likely to be 
of importance for the process of rejection. 
This chapter was published in Transplantation 48: 1039-1041, 1989 
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Introduction 
Cell membrane molecules coded by genes of the MHC play an essential role in the 
interaction between cells of the immune system and a transplanted organ (1). MHC 
class I molecules are expressed on most, if not all nucleated cells, whereas class ll 
molecules have a more restricted tissue distribution (2). MHC molecules of allograf-
ted tissue have the capacity to induce strong immune responses by activating T cells 
of the recipient. MHC class ll molecules appear to be stronger transplantation anti-
gens than class I molecules (3). Class ll antigens are recognized by T lymphocytes 
having the surface marker CD4, referred to as T helper cells (4). 
Activated T cells release IFN-y, a lymphokine that has the capacity to induce the 
expression of MHC molecules (5). IFN-y has been demonstrated to have a preferen-
tial effect on the expression of class ll antigens in a large number of cells (6,7). MHC 
class ll antigen expression may be enhanced in cells that constitutively express these 
molecules, or be induced de novo in cells that normally do not express them. 
It has been demonstrated that the degree of T cell activation in vitro is positively 
correlated with the amount of MHC class ll molecules on the stimulator cells (8). 
Grafts undergoing rejection are known to display an increased amount of class II 
antigens. These antigens can activate T cells that, subsequently, release IFN-y leading 
to enhanced class II expression and reinforcement of T cell activation. By this 
mechanism a vicious circle is maintained that, without interference, eventually will 
lead to rejection. Thus, enhancement of MHC class II antigen expression on cells of 
a donor organ prior to transplantation might result in a stronger immune response 
after allografting and early rejection of the transplant. 
The present study was initiated to test this hypothesis. Before cardiac allografts 
were transplanted, donor animals were treated with IFN-y to enhance the expression 
of MHC class ll antigens. 
Materials and methods 
Animals Male inbred BN (RT1u) rats were used as organ donors and Lewis (RT11) 
rats as recipients. The animals were bred under specific pathogen-free conditions, 
were 10-12 weeks old, and weighed 200-250 g. 
IFN-y Recombinant DNA-derived rat IFN-y (rRIFN-y) was a gift from Dr. P.H. 
van der Meide (ITRI-TNO, Rijswijk, The Netherlands). The protein was prepared 
from cultures of a transformed chinese hamster ovary cell line carrying the relevant 
gene encoding for rat IFN-y. Details about the methods of production and purifica-
tion have been described elsewhere (10). The rRIFN-y preparation used contained 
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2.5 x 106 laboratory reference unitsjmg protein. IFN-y was diluted in PBS at pH 7.8 
and administered i.v. with a flow of 0.5 ml/hr. 
Donor treatment During a period of 3 consecutive days, rRIFN-y was given by 
continuous intravenous infusion at dosages of 1oJ U /kg/hr (group I), 104 U /kg/hr 
(group II) and 5 x 104 U /kg/hr (group III). Controls (group IV) received PBS. All 
groups consisted of 9 animals. Continuous infusion was achieved by means of a 
catheter introduced into the jugular vein and connected to an external compression 
pump (Perfusor M, Braun Melsungen Ag, FRG). Infusion was started 3 days before 
and continued until the day of transplantation. Of each group 3 animals were 
sacrificed for immunohistologic staining; 1 animal per group was injected with 
Luconyl blue (see below) to visualize blood vessels, 5 min before sacrifice. 
Heart transplantation Heterotopic heart transplantations were performed as 
described previously (9). Cessation of heart beat was taken as moment of graft 
rejection. 
Luconyl staining Luconyl blue (No 708, BASF, FRG) is a dye consisting of 
macromolecules unable to pass the vascular endothelial lining. When injected 
intravenously, Luconyl blue remains in the vascular system and therefore can be used 
to identify vessels of any caliber in histologic sections. Luconyl blue was kindly 
provided by Dr. Reinhold (TNO, Rijswijk, The Netherlands). The dye was diluted 4:6 
in PBS and injected i.v. at a dose of 1.5 ml/rat. 
Immunoperoxidase staining OX-6 monoclonal antibody (Flow Laboratories, UK) 
was used to demonstrate MHC class II antigen expression. After removal, the hearts 
were embedded in Tissue Tek (Miles Laboratories, Naperville, USA), snap-frozen in 
liquid nitrogen, and cut in 5 J.Lm sections using a cryostat microtome (Bright Instru-
ment Comp, Huntingdon, UK) at -20 ° C. Frozen sections were mounted on glass sli-
des, allowed to air dry for 6 hr, fixed in acetone for 10 min, and washed 3 times in 
PBS. Subsequently, the sections were exposed for 45 min at room temperature in a 
moist chamber with OX-6 (1:100). Peroxidase-conjugated rabbit anti-mouse immuno-
globulin (Nordic, The Netherlands) was used as secondary step. Diaminobenzidine 
was used as chromogen. After each step the sections were washed 3 times in PBS. 
Finally, they were mounted in malinol. 
Counting of dendritic-like cells MHC class II positive dendritic-like cells were 
counted on immunoperoxidase and Luconyl-stained sections. The sections were 
studied using a high-power objective (magnification x200), with diameter of the area 
under view of 300 J.Lm. Fifteen fields were counted per section. 
Statistical analysis The Chi-square test was used to determine differences in survival 
times of cardiac grafts. Student's t test was used in the experiments analyzing the ex-
pression of class II antigens on dendritic-like cells after rRIFN-y treatment. In all 
cases, differences were considered to be significant at p<0.05. 
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Results 
Number of MHC class II positive cells 
Mter 3 consecutive days of continuous i.v. infusion of rRIFN-y, the number of MHC 
class ll positive cells in heart, liver and kidney was counted. A significant increase in 
the number of cells exhibiting MHC class ll expression was found in all organs 
examined (data for liver and kidney not shown). In heart tissue, a fourfold increase in 
the number of cells exhibiting class ll expression was seen, from 15 ± 4 to 61 ± 12 
(Table 7.1; p<0.005). The increase in number of class ll positive cells in rats infused 
with the low dose of rRIFN-y did not differ significantly from those receiving the high 
dosages, indicating the absence of a dose-response relationship in the dose-range 
used. 
MHC class ll positive dendritic-like cells were equally distributed among the 
myocardial cells and could clearly be distinguished from small vessels, such as capilla-
ries that were identified by Luconyl blue staining. Cardiomyocytes did not express 
class ll antigens after rRIFN-y treatment. The endocardium and endothelial cells of 
large arteries and venules remained negative as well. Induction of class ll positive 
endothelial structures was not observed in any of the examined organs. 
Table 7.1. Number of dendritic-like cells in hearts after treatment with rRIFN-y. 
rRIFN-y (U/hr) 0 1<f Hf 5.Hf 
number of 
positive cells 15±4 51±7 61±12 57±9 
/=2 
3 BN rats were treated with rRIFN-y by continuous infusion during 3 days. Data represent the mean ± 
SD of dendritic-like cells in heart. rRIFN-y significantly increased the numbers of dendritic-like cells 
(p<0.005). 
Graft survival 
The survival times of grafts obtained from rRIFN-y and PBS-treated donors were 
similar in all groups (Table 7.2). The mean survival times (±SD) were: 6.3 ± 0.5 days 
for the control group; 6.3 ± 0.5 days for group IT; 6.2 ± 0.4 days for group Ill; and 
6.5 ± 0.8 days for group IV. 
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Table 7.2. Effect of donor pretreatment with rRIFN-y on cardiac allograft survival 
group treatment survival( days) MST (±SD) 
I PBS 6,6,6,6,7,7 6.3 ± 0.5 
II ltrU/hr 6,6,6,6,7,7 6.3 ± 0.5 
III Hf U/hr 6,6,6,6,6,7 6.2 ± 0.4 
IV 5.HfU/hr 6,6,6,6,7,8 6.5 ± 0.8 
BN donors were treated with rRIFN-y by continuous infusion for 3 days. Controls were infused with 
PBS. Following infusion, BN hearts were transplanted immediately to untreated WAG recipients. 
Discussion 
In this study, it has been clearly demonstrated that rRIFN-y is able to enhance the 
expression of MHC class II in vivo. The enhancement of class II expression could be 
observed in different organs, including the heart. This finding confirms earlier 
observations made by ourselves and others (11,12). Analysis of MHC class II express-
ion on vascular and nonvascular cells was done. Distinction between both structures 
might be of importance, since it has been demonstrated that class II positive vascular 
endothelial cells not only may function as target but also as antigen presenting cells 
(13). As endothelial cells of the donor organ are the first allogeneic structures 
recognized by the host's immune system, induction of class II antigens on endothelial 
cells might be of utmost importance for initiation of rejection. In the current model, 
no vascular endothelial cells were shown to express class II antigens after rRIFN-y 
treatment. MHC class II expression was found on non-parenchymal non-endothelial 
dendritic-like cells, localized between cardiomyocytes. It is likely that a major 
proportion of these cells is identical to the dendritic cells, originally described by Hart 
and Faber (14). We did try to make a distinction between dendritic cells and tissue 
macrophages. It is well established that dendritic cells as well as macrophages express 
class II antigens and are able to function as antigen-presenting cells. In the allogenic 
situation, both cell types have been demonstrated to induce CD4-T cell dependent 
responses (15-17). Thus, enhancement of MHC class II positive cells within a donor 
organ, being expressed either by dendritic cells or tissue macrophages, might induce 
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reinforced immune responses by the host in both cases. However, in the present study 
it was found that a quantitative variation in the number of class II positive cells in the 
donor organ did not have any effect on the moment of graft rejection. 
This finding indicates that enhancement of class II antigens within the donor organ 
does not necessarily result in increased immunogenicity of the graft. It can be specula-
ted that the amount of class II antigens normally present on dendritic or dendritic-like 
cells within a graft is sufficient to induce adequate T cell activation. Subsequently, 
these activated T cells may lead to endogenous IFN-y production, overwhelming the 
effect of exogenous IFN-y. It should further be noted that in the current study an 
unmodified recipient was used. Consequently, the period needed to develop T cells 
primed against donor antigens may well have been a critical factor in the model used. 
Transplantation of MHC class II enriched organs to sensitized or immunosuppressed 
recipients leads to quite different results, as is described in chapter 9. 
Lechler has reported that the antigenicity of rodent allografts could be modulated 
by treatments leading to depletion of dendritic cells (17). He concluded that the APC 
of the graft provided the main signal to initiate allograft rejection. However, the role 
of class II antigens in a transplant appears to be complex and variable. In previous 
experiments, we only found a marginal effect of dendritic-like cell depletion on heart 
allograft survival (18). In addition, there is accumulating evidence that, depending on 
the donor-host combination used, different types of graft rejection, leading to varying 
patterns of class II antigen expression, may be operational (19). 
We and others have found that the unmodified rejection of rat cardiac allografts 
leads to induction of class II antigens on endothelial cells of the graft (20,21). It has 
been well established that endothelial cells expressing class II antigens have the 
capacity to induce strong immune responses (13). IFN-y has been demonstrated to 
induce the expression of class II antigens on endothelial cells in vitro and in vivo 
(11,12,22). This effect was not observed in the present study, which is probably due to 
the rat strain used (see chapter 5). Steiniger et al. were able to induce class II 
expression on endothelial cells of LEW rats by 3-day continuous infusion with IFN-y, 
using dosages that were within the range as used in our experiments (23). It thus 
seems that there exist marked differences in sensitivity for IFN-y between various rat 
strains. Unfortunately, in the experiments of Steiniger no transplantation experiments 
were included. Therefore, it remains to be investigated whether the presence of class 
II antigens on endothelial cells in a graft at the time of transplantation may have an 
effect on the process of rejection. 
In conclusion, in this study we have demonstrated that treatment with IFN-y in 
vivo may lead to a fourfold increase in the number of MHC class II antigen-expres-
sing, dendritic-like cells in hearts. However, transplantation of such class II antigen-
enriched hearts did not have an effect on graft rejection in the unmodified recipient. 
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Chapter 8 
DE NOVO INDUCTION OF DONOR MHC CLASS II ANTIGENS 
ON ENDOTHELIAL CELLS PRIOR TO TRANSPLANTATION HAS 
NO EFFECT ON ALLOGRAFT REJECTION 
Abstract 
In the present chapter we investigated the effect of MHC class II antigen expression 
on vascular endothelium on allograft rejection. LEW rats were treated with rRIFN-y 
to induce class II antigen expression on vascular endothelium of the graft prior to 
cardiac transplantation to WAG recipients. Expression of MHC class II antigens was 
demonstrated by immunoperoxidase staining using the monoclonal antibody OX-6. 
Vascular structures were identified by means of immunofluorescence staining using 
antibodies directed against FVIII, an endothelial surface antigen, or direct staining of 
the vascular lumen by means of Luconyl perfusion. Treatment of LEW rats with 
rRIFN-y induced the expression of MHC class II antigens on vascular endothelium of 
arteries and veins, but not on endothelium of capillaries. No expression was found on 
cardiomyocytes. The induction of MHC class II antigen expression on vascular 
endothelium prior to transplantation had no effect on graft survival. This suggests that 
de novo expression of MHC class II antigens on vascular endothelium of a graft does 
not imply increased immunogenicity and accelerated graft rejection. 
This chapter has been submitted for publication 
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Introduction 
It is well established that allograft immunogenicity is mainly dependent on the 
presence of MHC antigens (1,2). A quantitative relationship between MHC antigen 
expression and T cell mediated responses has been demonstrated in vitro (3,4). MHC 
class IT antigens appear to be stronger transplantation antigens than class I molecules 
(5). They play a pivotal role in the initiation of graft rejection by activating helper T 
cells (6) that subsequently release immunostimulatory cytokines, such as IL-2, IL-4, 
1NF-a and IFN-y (7,8). The expression of class IT antigens is variable and dependent 
on immunologic stimuli. Immunosuppressive drugs such as corticosteroids (9) and 
cyclosporine (10) reduce MHC antigen expression. Alternatively, upregulation of 
MHC class IT antigen expression on graft cells is observed during allograft rejection 
(11,12). MHC class IT antigen expression may be intensified on cells that constitutive-
ly express these antigens and induced de novo on cells that are class ll negative under 
non-stimulatory conditions. Enhancement of MHC class ll antigen expression on 
donor cells is thought to amplify T cell activation and facilitate alloreactive immune 
responses. Most recently however, it was demonstrated that an increase in the number 
of interstitial MHC class ll positive cells within a heart graft prior to transplantation 
did not effect acute graft rejection in the rodent model (13). It was speculated that 
endothelial cells, being the first graft cells encountered by the host immune system 
and induced to express class ll antigens de novo, would be of more importance to 
facilitate acute graft rejection (14). Endothelial cells expressing class ll antigens may 
function as APC (15,16) and activate allogeneic lymphocytes (17,18). Ferry et al. 
found that the extent of the immunogenic potential of highly purified rat heart endo-
thelial cells was directly proportional to the expression of MHC class ll antigens on 
the cell surface (19). These findings suggest that the immunogenicity of a vascularized 
graft would be significantly enhanced if endothelial cells are induced to express class 
n antigens, thereby facilitating graft rejection. 
In the present study a rat model is used in which de novo expression of MHC class 
ll antigens can be induced on vascular endothelial cells by rRIFN-y treatment. 
Earlier, it has been reported that class ll antigen reactive endothelial cells remain 
detectable until 4 days after rRIFN-y withdrawal (20). In the current experiments the 
effect of increased MHC class II expression on vascular endothelial cells on acute 
rejection is studied. 
Materials and methods 
Animals MHC class I and II incompatible rat strains were used. Male LEW (RT11) 
rats were selected as organ donors and WAG (RT1u) rats as recipients. The animals 
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were 10-12 weeks old, weighed 200-250 g, and were bred under specific pathogen free 
conditions. 
Heart transplantation Heterotopic heart transplantations were performed as de-
scribed previously (21). Briefly, an anastomosis was made between the aorta and 
pulmonary artery of the donor heart and the aorta and caval vein of the recipient, 
respectively. The transplanted hearts were checked by daily palpation. Rejection was 
diagnosed by cessation of heart beat and confirmed by histologic examination. 
IFN-r Recombinant DNA-derived rat IFN-y (rRIFN-y) was prepared from cul-
tures of a transformed chinese hamster ovary cell line carrying the relevant gene 
encoding for rat IFN-y. Details about the methods of production and purification 
have been described elsewhere (22). The rRIFN-y preparation used contained 2.5 x 
106 laboratory reference units per mg protein. The product was diluted in PBS at pH 
7.8 and administered with a flow of 0.5 rnl/hr. 
Luconyl staining Luconyl blue (No 708, BASF, FRG) is a dye consisting of 
macromolecules unable to pass the vascular endothelial lining. When injected intra-
venously (i.v.), Luconyl blue remains within the vascular system and therefore can be 
used to identify vessels of any caliber in histological sections. Luconyl blue was kindly 
provided by Dr. Reinhold (I1RI-TNO, Rijswijk, The Netherlands). The dye was 
diluted 4:6 in PBS and injected i.v. at a dose of 1.5 rnl/rat. 
Immunoperoxidase staining OX-6 and F-17 monoclonal antibodies (Flow Laborato-
ries, England) were used to demonstrate MHC class II antigen expression. OX-6 
monoclonal antibodies react with class II antigens of both LEW and WAG rats, 
whereas F-17 antibodies only react with class II antigens of LEW rats. After removal, 
hearts were embedded in Tissue Tek (Miles Laboratories, Naperville, USA), snap-
frozen in liquid nitrogen, and cut in 5 J,Lm sections using a cryostat microtome (Bright 
Instrument Comp, Huntingdon, England) at -20 ° C. Frozen sections were mounted on-
to glass slides, allowed to air dry for 6 hr, fixed in acetone for 10 min and washed 3 
times in PBS. The sections were exposed to OX-6 (1:100) for 45 min. at room tempe-
rature in a humidified atmosphere. Peroxidase-conjugated rabbit anti-mouse immuno-
globulin (Nordic, The Netherlands) was used as secondary step. Diarninobenzidine 
was used as chromogen. After each step the sections were washed 3 times in PBS. 
Finally, they were mounted in manilol. 
Indirect immunofluorescence A specific rabbit antiserum, binding to human factor 
VIII and crossreacting with rat factor VIII (RAHu/FVIII, Nordic, The Netherlands), 
was used to identify vascular structures. Sections were exposed to RAHu/FVIII 
(1:25), OX-6 (1:100), goat-anti-rabbit fluorescein-isothiocyanate (GAR/FITC ;1:25) 
and goat-anti-mouse tetramethylrhodarnine isothiocyanate (GAM/1RITC; 1:25), 
respectively for 45 min. at room temperature in a humidified atmosphere. NaN3 
(0.02%) was added to all incubation steps, 10% normal BN serum to the first two and 
2% to the latter two steps. After each step the sections were washed 3 times in PBS. 
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Finally, the sections were air dried and mounted in PBS/glycerol (1:20). The prepar-
ations were examined using a Zeiss Universal Microscope equipped with an epi-
illuminator IIIRS and filters for FITC and TRITC fluorescence. 
Donor treatment In the first series of experiments six heart transplantations were 
performed using untreated LEW rats as donors and WAG rats as recipients (group I). 
In a second series of experiments lEW rats were treated with PBS (group II) or 
rRIFN-y (group ill) before heart transplantation was performed. PBS and rRIFN-y 
(lOS U/kg/hr) were given by continuous intravenous infusion during 2 days and 
continued until the day of transplantation. Group II and III consisted of 9 animals, 3 
of which were killed for immunohistological staining. One animal of each group was 
injected with Luconyl blue, 5 min before sacrifice. Continuous infusion was achieved 
by means of a catheter introduced into the jugular vein and connected to an external 
compression pump (Perfusor, Braun, Melsungen, FRG). Following donor pretreat-
ment hearts were transplanted to unmodified WAG recipients. 
Statistical analysis Chi-square test was used to analyze differences in survival times 
of cardiac grafts. Differences with p-values smaller than 0.05 were considered to be 
significant. 
Results 
Patterns of MHC class II antigen expression 
Interstitial dendritic-like cells were found the only sessile structures expressing MHC 
class II antigens in hearts of control LEW rats (Fig 8.la). These interstitial cells were 
equally distributed among class II negative cardiomyocytes. Using immunoperoxidase 
and immunofluorescence techniques MHC class II and FVIII antigens could be 
detected. The localization of MHC class II antigen positive structures clearly differed 
from that of FVIII positive structures. Small vessels such as capillaries did react with 
FVIII but not with anti-class II antibodies. By means of Luconyl perfusion of the 
donor heart, vascular structures could be identified before immunohistologic sections 
were made. Concomitant immunoperoxidase staining using antibodies directed against 
class II antigens confirmed the results obtained by immunofluoresence techniques. A 
comparable vascular pattern was found and capillaries could easily be discriminated 
from MHC class II positive interstitial dendritic-like cells. Endothelial cells of large 
arteries and veins as well as endocardium did not express MHC class II antigens. 
Rejected grafts were studied to compare the pattern of MHC class II expression 
induced by endogenous cytokines released during rejection with the one observed 
after exogenous rRIFN-y treatment. Immunohistologic analysis of LEW cardiac allo-
grafts rejected by WAG rats (group I) did show a marked increase in the number of 
cells expressing class II antigens (Table 8.1). These cells were equally distributed 
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Table 8.1. Expression of MHC class II antigens in hearts of LEW rats. 
cellular structure control rRIFN-y rejection 
Interstitial cells + ++ ++ 
Endothelium arteries - + + 
veins - + + 
capillaries 
Endocardium - + + 
Cardiomyocytes 
rRIFN-y (10" Ujkg/hr, 2 days) was administered by continuous infusion. Hearts of LEW rats were 
transplanted to untreated WAG rats to study the pattern of MHC class II expression induced by 
rejection. 
among myocardial cells. Using LEW strain specific antibodies (F-17) the enhanced 
MHC class II antigen expression could be demonstrated not to be of donor origin, but 
instead host derived. Vascular endothelial cells of large arteries and veins were found 
to express class II antigens, whereas endothelial cells of capillaries remained class II 
negative. MHC class II antigen expression on vascular endothelium was demonstrated 
to be of donor origin by using strain specific antibodies (F-17) against LEW class II 
antigens. The phenotypic appearance of cardiomyocytes remained unchanged as far as 
the expression of class II antigens was concerned; expression of class II antigens could 
not be demonstrated intracellularly or on the cell surface of these parenchymal cells. 
The pattern of class II antigen expression in hearts of LEW rats following rRIFN-y 
treatment was comparable to that of rejected LEW cardiac allografts described above. 
A marked expression of class II antigens on vascular endothelial cells of larger vessels 
was seen (Fig. 8.1b ). Capillaries were found to be negative for MHC class II antigens 
as studied by immunofluorescense and Luconyl staining techniques. In addition, car-
diomyocytes of rRIFN-y treated donors did not express class II antigens intracel-
lularly or on their membranes either. Examination of HE sections by light microscopy 
did not show any signs of rRIFN-y induced cellular damage of parenchymal or non-
parenchymal structures. 
Effect on graft survival 
Graft survival of rRIFN-y pretreated donor hearts of LEW rats transplanted to WAG 
recipients did not differ from that of controls pretreated with PBS (Table 8.2). 
Microscopic examination of rejected grafts revealed no differences in histology 
between transplants of experimental and control rats. 
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Table 8.2. Graft survival times of LEW hearts transplanted to WAG recipients. 
group 
I 
II 
m 
treatment 
none 
PBS 
rRIFN-y 
survival( days) 
9,9,9,19,21 
11,11,11,17,17,19 
10,11,11,12,16,17 
Mean± SD 
13.4 ± 6.1 
14.3 ± 3.7 
12.8 ± 2.9 
Prior to heart transplantation LEW rats were treated with rRIFN-y at a dosage of lOS U /kg/hr for 2 
days. 
Discussion 
The results presented in this study demonstrate that rRIFN-y treatment leads to de 
novo induction of MHC class ll antigen expression on cardiac vascular endothelial 
cells comparable to that observed during acute cardiac allograft rejection. In contrast 
to reports by others (19,25) class ll antigen expression was not found on capillary 
vascular endothelium or cardiomyocytes. Deleterious effects of rRIFN-y treatment on 
heart parenchymal and non-parenchymal cells were not observed, confirming recent 
data indicating that MHC expression may be induced in the absence of cell injury 
(23). 
Our results demonstrate that the presence of enhanced class II antigen expression 
on endothelial cells at the moment of transplantation does not facilitate acute graft 
rejection. This finding throws doubt upon the importance of the presence of class n 
positive vascular endothelium to graft immunogenicity in vivo as suggested by others 
(10,12-16). It may be explanatory that most of these studies were performed in vitro 
under well-defined conditions, whereas our results were obtained in an experimental 
model using unmodified recipients. More potent immune mechanisms might overrule 
immunostimulating activities of endothelial cells in vivo. To our knowledge there is 
only circumstantial evidence to support the hypothesis that class ll antigen expression 
on vascular endothelial cells is of importance to graft immunogenicity in vivo. It is 
well recognized that induction of class II antigens and infiltration of leukocytes into 
an allograft are closely interrelated events and acute graft rejection almost never 
occurs without increased MHC class II expression (24). Moreover, Ruers et al. 
reported that intrarenal administration of corticosteroids to rat kidney allografts leads 
to reduced donor class II antigen expression and prolonged allograft survival (25). 
They found that the cellular infiltrate of treated and untreated grafts was comparable, 
whereas the expression of MHC class II antigens on renal target cells differed. 
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The absence of class ll expression on renal target cells of treated rats was suggested 
to be responsible for the prolonged survival. However, others have reported 
contradicting results studying long-surviving rat kidney grafts (22,26). They described 
the presence of a cellular infiltrate concomitantly with an increased expression of 
class ll antigens in non-rejected grafts. These data are in agreement with findings of 
ourselves (unpublished) and others (27) in the rat heart transplantation model 
showing that long surviving cardiac allografts may express class ll antigens on vascular 
endothelium without being rejected. 
There is no uniformity concerning the changes in the expression of class ll antigens 
during acute rejection, whereas most studies report similar changes in the expression 
of class I antigens during rejection (28). This lack of uniformity concerning class ll 
antigen expression may be explained by the use of different experimental models. 
Forbes et aL investigated the pattern of class ll expression within rat cardiac allografts 
using different donor-recipient combinations (29). They found that in certain strain 
combinations acute graft rejection occured in the absence of donor class ll antigen 
expression on vascular endothelium, whereas in other combinations prolonged graft 
survival was observed in the presence of class II antigen expression on arterial 
endothelium. In addition, Sachs et aL demonstrated that differences between mice 
strains for class II antigens may not in themselves constitute transplantation antigens 
capable of causing acute graft rejection, but that additional genetic differences might 
be needed to induce acute graft rejection (30). 
It is well established that graft immunogenicity may be reduced by down-regulation 
of class II antigen expression on APC (24,31,32). However, as our results show, this 
concept does not imply that upregulation of these antigens on APC, e.g. on en-
dothelial cells, enhances immunogenicity. These data are in agreement with our 
earlier findings indicating that an increase in the number of class ll positive 
interstitial dendritic-like cells within a graft prior to transplantation has no influence 
on acute graft rejection (13). 
It is likely that acute graft rejection is initiated when a number of donor APC 
exceeds a certain threshold. These APC can be represented by dendritic or endothe-
lial cells (33). Once rejection is initiated a cascade of events will take place that is 
independent of the potency of the primary stimulation. However, upregulation of 
MHC class II antigen expression may affect acute graft rejection by recipients whose 
immune system has been modified. Thus, in rodents MHC class II enriched skin 
grafts have been shown to be rejected more rapidly by weakly immunosuppressed dr 
sensitized recipients than unmodified recipients (34, see also Chapter 9). This finding 
indicates that there are certain conditions, defined by the recipient's immune system, 
in which an increase of MHC class II antigen expression on grafts affect the outcome 
of rejection. 
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• 
Figure 8.1. Expression of MHC class II antigens on cardiac structures of LEW rats. (a) 
Photomicrograph of a control heart showing MHC class II antigen expression on an interstitial cell 
(arrow), but not on endothelial cells or cardiomyocytes. x 600. (b; facing page) Photomicrograph of a 
vessel showing MHC class II antigen expression on endothelial cells (arrow) after rRIFN-y treatment. x 490. 
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Chapter 9 
ACCELERATED REJECTION OF MHC CLASS II ANTIGEN 
ENRICHED GRAFTS BY IMMUNOMODIFIED RECIPIENTS 
Abstract 
Allogeneic MHC class ll antigens play an important role in the initiation of T cell 
activation leading to graft rejection. In this chapter a rat model was used in which 
MHC class II expression was induced on epidermal skin cells of LEW rats prior to 
skin transplantation by continuous i.v. infusion of rRIFN-y at a dosage of 1.5 x lOS 
U /kg/hr for 2 consecutive days. Induction of class ll expression on epidermal skin 
cells was evaluated by immunoperoxidase staining using the monoclonal antibody 
OX-6. After pretreatment skin grafts were transplanted to unmodified, sensitized and 
i~unosuppressed WAG rats. Graft survival in unmodified recipients was unchanged 
when compared to controls (MST 9.5 ± 0.14 vs 9.75 ± 0.14), whereas a shortened 
graft survival was found on sensitized (MST 5.3 ± 0.14 vs 6.1 ± 0.10; p<O.Ol) and 
CsA immunosuppressed recipients (MST 12.5 ± 0.42 vs 11.1 ± 0.23; p<0.04). It can 
be concluded that upregulation of MHC class II antigen expression does not affect 
unmodified immune responses, but may accelerate rejection if immune responses are 
modified. 
This chapter was published in a modified form in Transplant Proc 22: 1941-1942, 1990. 
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Introduction 
The initiating event in the induction of immune responses requires the interaction 
between antigen-presenting cells (APC) and T lymphocytes that recognize antigen in 
complex with molecules of the MHC expressed on cell membranes (1,2). It is well 
established, that MHC antigens of allografted cells have the capacity to induce strong 
immune responses (3). MHC class I molecules are mainly recognized by CD8 T cells 
and class II molecules by CD4 T cells ( 4,5). 
IFN-y appears to have a preferential effect on the expression of class II molecules 
and has been demonstrated to induce transcription of class II genes in cells that 
normally do not express these molecules (6,7). Upon exposure to IFN-y, cells may 
display a qualitative and quantitative variation in class II expression. Marked changes 
in the expression of MHC class II antigens on allografted cells have been observed 
during the rejection of grafts, including skin (8,9). It is assumed that IFN-y, released 
by activated CD4 T cells during the process of rejection, may induce this phenome-
non in vivo. The immunologic relevance of this effect remains to be determined. In 
vitro it has been demonstrated that the degree of T cell activation is positively 
correlated with the concentration of MHC molecules on target cells (10). If the same 
mechanism is operative in vivo it follows that immune reactions will be facilitated and 
the process of graft rejection accelerated by enhanced MHC expression. 
The present study was initiated to investigate the immunologic relevance of 
enhanced graft MHC class II expression at the moment of transplantation on the 
outcome of rejection. Using a rat model, donor pretreatment with rRIFN-y was used 
to induce class II antigen expression on cells of a skin graft. The process of skin graft 
rejection was studied using unmodified, sensitized or weakly immunosuppressed 
recipients. 
Materials and methods 
Animals Male inbred Lewis rats (RT11) were used as skin donors and WAG rats 
(RT1u) as recipients. The animals were 10-12 weeks old, weighed 200-250 g, and were 
bred under specific pathogen free conditions. 
IFN-y Recombinant DNA-derived rat IFN-y (rRIFN-y) was kindly provided by 
Dr. P.H. van der Meide (ITRI-TNO, Rijswijk, The Netherlands). The protein was 
prepared from cultures of a transformed chinese hamster ovary cell line carrying the 
relevant gene encoding for rat IFN-y. Details about the methods of production and 
purification have been described elsewhere (11). The rRIFN-y preparation used, 
contained 2.5 x 106 laboratory reference units per mg protein. The product was 
diluted in PBS at pH 7.8 and administered at a flow of 1.0 ml/hr. 
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Donor treatment During a period of 2 consecutive days rRIFN-y was given by 
continuous intravenous infusion at a dosage of 1.5- x lOS U /kgjhr (group II, IV and 
VI). In chapter 5 we demonstrated that this treatment leads to MHC class II expres-
sion. Controls (group I, III and V) received PBS in the same volume and pH of 7.8. 
Groups consisted of at least 8 animals. Continuous infusion was achieved by means of 
a catheter introduced into the jugular vein and connected to an external compression 
pump (Dascon, Uden, The Netherlands). After rRIFN-y infusion, a period of 12 hrs 
was waited before transplantations were started. This interval permitted maximum 
expression of rRIFN-y induced class II antigens on the cell surface. Of each group, 
skin biopsies were taken for immunohistological staining. 
Sensitization of the recipient To obtain highly sensitized recipients, WAG rats were 
treated 2 times by LEW skin grafting, 4 and 2 weeks before the current experiments. 
Immunosuppression Cyclosporine A (CsA) was used at a dosage of 50 mg/kg at 
day 0 and day 2 after transplantation. CsA was dissolved in olive oil and administered 
by intramuscular injection. 
Immunoperoxidase staining The monoclonal antibody OX-6 (Flow Laboratories, 
England) was used to demonstrate MHC class II antigen expression. After removal, 
skin biopsies were embedded in Tissue Tek (Miles Laboratories, Naperville, USA), 
snap-frozen in liquid nitrogen, and cut in 5 ).£m sections using a cryostat microtome 
(Bright Instrument Comp, Huntingdon, England) at -20 o C. Frozen sections were 
mounted on to glass slides, allowed to air dry for 6 hours, fixed in acetone for 10 min 
and washed 3 times in PBS. The sections were exposed to OX-6 (1:100) at room 
temperature in a humidified atmosphere for 45 min. Peroxidase-conjugated rabbit 
anti-mouse immunoglobulin (Nordic, Tilburg, The Netherlands) was used as secon-
dary step. Diaminobenzidine was used as chromogen. After each step the sections 
were washed 3 times in PBS. Finally, they were mounted in manilol. 
Skin transplantation Full thickness skin transplantation was performed as follows: 
donor animals were anaesthesized with aether, the abdomen shaved and cleaned with 
PBS. Abdominal skin grafts, 1.5 em in diameter, were resected and the panniculus of 
the grafts was removed with scissors. Subsequently, recipients were anaesthesized with 
aether, the dorsal thoracic area shaved, cleaned with alcohol and covered with 
adhesive tape. The taped area was lifted and a circular piece of skin, identical to the 
donor part, removed. The skin graft was fitted into the graft bed, which maintained 
shape and position due to the surrounding tape. A dressing of paraffin impregnated 
gauze and tissue paper was applied and covered with fixing tape wrapped around the 
thorax. Five (group V and VI) or 7 days (group I, II, III and IV) after transplanta-
tion, the dressing was removed. Graft survival was evaluated macroscopically. 
Complete necrosis of epidermal tissue was. taken as the endpoint of graft survival. 
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Statistical analysis Fisher's test were used to analyse differences in survival times of 
skin grafts between distinct groups. Differences were considered to be significant at a 
p<O.OS. 
Results 
Induction of MHC class II antigen expression 
In skin biopsies of rats treated with PBS, the presence of class ll antigens was 
confined to dendritic-like cells scattered around in the dennis and occasionally in the 
epidennis (Fig. 9.1a). Vascular endothelial cells were negative in all skin biopsies 
taken from control animals. Skin biopsies of animals treated with rRIFN-y (Fig. 9.lb) 
displayed a marked increase of MHC class ll antigen expression. Induction of class ll 
antigens was found on cells, located in the basal and spinous layers of the epidermis, 
around hair follicles and in the dennis. In the dermal layer class ll antigens were 
expressed by dendritic-like cells and vascular endothelial cells. Antigen was expressed 
on the surface of cells as well as in the cytoplasma, suggesting that rRIFN-y indeed 
induced the de novo synthesis of class ll antigens and membrane-bound antigens were 
not acquired passively from other sources in the environment. 
Figure 9.1. Photomicrograph of a skin specimen showing the dermal and epidermal layers of PBS (a) 
and rRIFN-y (b) treated LEW rats; an increase in the number of MHC class II positive structures can 
be observed after rRIFN-y treatment (immunperoxidase staining using anti-MHC class II monoclonal 
antibody OX-6). x 90. 
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Skin graft survival 
In unmodified recipients transplantation of skin grafts enriched for MHC class II 
antigens resulted in graft survival times identical to those of allografted control skins 
(Table 9.1). In both groups skin grafts were rejected in 9-10 days. Enhanced class II 
expression on the moment of transplantation had a significant effect on graft rejec-
tion by sensitized animals. In the experimental (group IV; MST 5.3 ± 0.14) as well as 
control group (group III; MST 6.1 ± 0.10) a marked acceleration of skin graft 
rejection by sensitized recipients was found, when compared with the moment of re-
jection by unmodified recipients (group I; MST 9.5 ± 0.14). Skin grafts of rRIFN-y 
treated donors were rejected more rapidly by sensitized recipients than those of 
controls. After removal of the dressing on the fifth postoperative day, complete rejec-
tion was found in 8 out of 12 skin grafts obtained from rRIFN-y pretreated donors. 
Six days after grafting all skin transplants of rRIFN-y treated donors were rejected. 
Rejection of skin grafts in the control group occurred on day 6 in 9 out of 10 animals, 
significantly later than in the experimental group (p<0.001; Fisher's test). 
Recipients treated with CsA displayed a difference between the moment of rejec-
tion of skin grafts of PBS (group V) and rRIFN-y (group VI) treated donors. It was 
found, that skin grafts from rRIFN-y treated donors were rejected significantly earlier 
than those of PBS treated donors ( MST 11.1 ± 0.23 vs 12.5 ± 0.42; p<0.04, Fisher's 
test). 
Table 9.1. Survival time of pretreated skin grafts transplanted to modified recipients. 
group treatment n MST (days) p 
donor recipient 
I PBS 14 9.5 ± 0.14 ns 
II rRIFN-y 16 9.8 ± 0.14 
III PBS sens 10 6.1 ± 0.10 <0.001 
IV rRIFN-y sens 12 5.3 ± 0.14 
v PBS CsA 8 12.5 ± 0.42 <0.04 
VI rRIFN-y CsA 8 11.1 ± 0.23 
Skin grafts from PBS or rRIFN-y treated LEW rats were transplanted to unmodified (I,II), sensitized 
(III,IV) and immunosuppressed (V,VI) WAG rats. rRIFN-y was given by continuous i.v. infusion (1.5 x 
10' U/kg/hr for 2 days). MST: mean survival time ± SEM. 
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Discussion 
The induction of MHC class II antigen expression during allograft rejection is thought 
to play a significant role in graft rejection. In skin, these antigens are mainly found on 
dendritic-like cells, defined as the bone-marrow derived Langerhans's cells, located in 
the dermal layer. Normally, rat epidermal skin cells do not express class II antigens. 
However, they can be induced de novo on epidermal skin cells (keratinocytes), as was 
first reported by Lampert (12) and Mason( B). They showed that keratinocytes of rats 
suffering from graft-versus-host disease express MHC class II antigens and demon-
strated that these antigens were produced by the keratinocytes themselves and were 
not passively acquired from other positive cells such as the Langerhans's cells (14). It 
has also been demonstrated that keratinocytes of skin allografts express class II 
antigens during skin graft rejection (15). Today, it is well documented that IFN-y, 
released by activated T cells, induces the expression of MHC class II antigens (6,7). 
In the present study we demonstrated that IFN-y treatment leads to de novo MHC 
class II antigen expression on keratinocytes of normal rat skin. Expression was found 
on keratinocytes located in the basal layers of the epidemis, around hair follicles, and 
on dendritic-like cells scattered around in the dermis. These findings are in 
agreement with those reported by Steiniger et al. (16). In addition, they studied the 
disappearance of rRIFN-y induced class II antigens in vivo and noted that the 
expression on keratinocytes remained detectable at least untill the sixth day after 
induction. 
We studied the immunologic relevance of induced class II antigen expression using 
an allogeneic skin transplantation model. The experimental results demonstrate that 
enhanced class II antigenicity of skin grafts has no effect on the moment of graft 
rejection by unmodified recipients. However, skin grafts obtained from rRIFN-y 
treated donors were rejected significantly more rapidly by sensitized as well as weakly 
immunosuppressed recipients. It follows, that enhancement of class II antigen ex-
pression on skin grafts may correlate with increased immunogenicity. It is known that 
CsA suppresses class II antigen expression. Skin grafts of rRIFN-y treated donors, 
enriched for class II antigens, may have annulled this CsA effect and provided 
immunologic stimuli, i.e. class II antigens, that surpassed the CsA-induced 
immunosuppression of the affector pathway. 
The shortened survival times of rRIFN-y treated skin grafts transplanted to 
sensitized recipients may be attributed to a more powerful effector pathway of 
rejection due to the presence of primed effector cells directed against class II 
antigens. It is well documented that CD4 T cells may function as effector cells and 
exert direct cytotoxicity to allografted cells expressing class II antigens (17, 18). 
rRIFN-y might also have increased MHC class I antigen expression on skin grafts, 
thereby stimulating CDS T cells mediated rejection. Similar findings have been 
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reported by others studying pancreatic islet allograft immunogenicity and rejection 
after IFN-y treatment (19,20). 
In contrast to skin graft rejection by modified recipients, rejection by unmodified 
recipients was not changed by rRIFN-y pretreatment. This observation is in agree-
ment with findings in an allogeneic heart transplantation model in rodents. These 
findings suggest that the amount of donor MHC class II antigens normally present 
within a graft suffices to stimulate CD4 T cells to a maximum if the recipient's 
immune system is not compromized in one way or the other (i.e. sensitization or im-
munosuppression). 
In conclusion, the results of the current experiments indicate that upregulation of 
allogeneic MHC class II antigen expression is of minor importance to the unmodified 
rejection process; however, if the recipient's immune system is modified by 
sensitization or suppression, upregulation of MHC class II antigen expression can 
accelerate immune responses. 
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Chapter 10 
SUCCESSFUL TREATMENT OF COLON CANCER IN RATS WITH rRIFN-y 
Abstract 
The antiproliferative activity of rRIFN-y was tested against a weakly immunogenic 
colon adenocarcinoma (CC531) in vitro and in vivo. Tumor cell suspensions of CC531 
were incubated with different dosages of rRIFN-y to assess a direct antiproliferative 
effect. No antiproliferative effects of rRIFN-y were found after a three-days in-
cubation period. 
In vivo antiproliferative activities were tested in a subrenal capsule assay (SRCA) 
and a liver metastases model. In the SRCA, intravenous treatment with rRIFN-y at a 
dosage of 5x10S U/kg/day for 5 consecutive days, starting at the day of tumor implan-
tation, did result in a significant inhibition of tumor growth (p < 0.05). In the liver 
metastases model the same treatment schedule with rRIFN-y, started at the day of 
CC531 tumor cell injection into the portal vein, significantly inhibited the 
development of liver metastases (p<0.001). 
In conclusion, rRIFN-y can exert an impressive anti-tumour activity in vivo, while 
direct cytotoxicity in vitro is absent. Indirect mechanisms, such as changes of target 
cells or host immune functions, may be responsible for the inhibition of tumor growth 
and dissemination by rRIFN-y. 
This chapter has been published in Br J Cancer 56: 795-796, 1987. 
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Introduction 
The lymphokine IFN-y is produced by mitogen or antigen-stimulated T lymphocytes 
(1,2). Compared to IFN-a and -13 several differences in biologic activity have been 
reported, particularly in relation to its immunomodulating and antiproliferative 
properties. Evidence from in vitro and in vivo studies suggests that IFN-y may have a 
much greater antitumor effect than either IFN-a or -J3 (3,4). IFN-y has been reported 
to exert a direct cytotoxic effect on certain tumor cell lines (5,6). In addition, a 
number of immunological functions influenced by IFN-y may synergize with this 
direct cytotoxic action. It has been demonstrated that IFN-y can enhance monocyte 
cytotoxicity (7,8,9), macrophage activity and natural killer (NK) cell activity (10,11). 
Furthermore, IFN-y can enhance the expression of surface antigens on tumor cells 
(12,13) and on cells of the host immune system, i.e. macrophages (14,15,16), which 
may facilitate tumorcell lysis. Despite the well-recognized antiproliferative effects of 
IFN-y in vitro, the mechanism(s) of its action in vivo are still poorly understood. 
Recent advances in molecular biology and recombinant DNA technology have 
resulted in the production of highly purified rat IFN-y. The present study was 
undertaken to evaluate the antitumor activity of this preparation in vitro and in vivo, 
using a rat colon adenocarcinoma (CC531), which was previously found to be 
susceptible to treatment with immune response modifiers (17,18,19). 
Materials and methods 
Animals Male rats of the inbred WAG strain were used. The animals were bred 
under specific pathogen-free conditions, weighed about 200 g and were 10-12 weeks 
old. 
Tumor Tumor CC531 is a 1,2 dimethylhydrazine-induced, moderately differentiated 
adenocarcinoma of the colon, originating from a male WAG rat (17). The tumor is 
transplantable in syngeneic animals and is weakly immunogenic as determined by in 
vivo challenge-protection experiments according to the method of Prehn and Main 
(20). In the experiments presented here, the tumor was in its 19th passage. The tumor 
is also maintained in tissue culture as a stationary cell line in RPMI-1640 medium 
(Gibco, UK), supplemented with 10% fetal calf serum (FCS). Tumor cell suspen-sions 
were prepared from culture monolayers by trypsinization for 2 min and resus-pension 
in fresh medium. 
IFN-y Recombinant DNA-derived rat IFN-y (rRIFN-y) was kindly provided by 
Dr. P.H. van der Meide. Details of the cloning, expression and purification have been 
reported elsewhere. The preparation used in the current experiments contained 4 x 
106 U per mg protein and had a purity of 98%. The antiviral units were estimated by 
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determining, in serial dilutions, the protective effect of rRIFN-y against vesicular 
stomatitis virus infection of rat fibroblast monolayers in a microtiter assay. 
Experimental design To assess whether rRIFN-y had a direct antiproliferative effect 
on tumor CC531, cells were harvested from culture by trypsinization. After washing 
lOS cells in 4 ml RPMI-1640 with 10% FCS were pipetted into 35mm tissue culture 
plates (Costar). One ml of RPMI 1640, containing 2000, 4000 or 8000 units of rRIFN-
Y was added and the plates were incubated at 37 ·C. After 3 days the number of cells 
per plate was counted in a microcell counter (TAO, Japan) and the percentage of 
living cells determined by Trypan blue dye exclusion. Each dose-experiment was in 
triplicate. In the control plates only RPMI 1640 was added. 
Subrenal capsule assay The first in vivo model used was the subrenal capsule assay 
(SRCA), which was performed as follows. WAG rats (5 animals per group) were 
anesthized with ether, a median laparotomy was performed and both kidneys exposed. 
A small incision was made in the renal capsule and a tumor cube of 6-8 mg, obtained 
from the 19th passage, was implanted and pushed up to the upper kidney pole. The 
animals were killed one week later and the tumors removed and weighed. 
Liver metastases model The second in vivo model was a liver metastases model. 
Artificial liver metastases were evoked by injection of 5 x lOS tumor cells into the 
portal vein. Under ether anesthesia the portal vein was exposed via an abdominal 
midline incision and 0.5 ml of the cell suspension was injected using a 0.4 x 12 mm 
needle. The rats were laparotomized 30 days after tumor cell inoculation and the 
number of liver nodules visible at the surface of the liver lobes, inspected in situ, was 
counted. Each experimental group contained 6-7 animals. In the liver metastases 
experiments and the SRCA, rRIFN-y was administered i.v. at a daily dose of 5 x lOS 
U /kg in a volume of 0.5 ml for 5 consecutive days, starting at the day of tumor 
implantation. 
Statistics Experimental data were analyzed using Student's t test. Differences were 
considered to be significant at p<0.05. 
Results 
As shown in Table 10.1 CC531 tumor cells were not susceptible to treatment with 
rRIFN-y in vitro. None of the concentrations of rRIFN-y used resulted in inhibition 
of cell proliferation. The number of cells counted after a 3 days incubation period was 
similar in all cases. There was no difference in the percentage of dead cells between 
control and experimental groups. Table 10.2 shows the effect of rRIFN-y on tumor 
CC531 as measured in the SRCA It was found that treatment with rRIFN-y led to a 
significant inhibition of tumor growth (p<0.05). The mean tumor weight of the 
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Table 10.1. Susceptibility of CC531 tumor cells to direct cytotoxicity of rRIFN-y 
rRIFN-y n Dead cells 
inactivated 15.0 ± 3.2 X 1Q' 9.6 ± 0.6 
2000 U/well 14.6 ± 3.5 X 1Q' 13.0 ± 3.4 
4000 U/well 14.4 ± 3.2 X 1Q' 12.6 ± 4.6 
8000 U/well 14.8 ± 2.4 X 1o' 8.0 ± 3.6 
1o' tumor cells were cultured with rRIFN-y for 3 days; the total number was counted (n: M ± SD) and 
the percentage of dead cells was determined by means of trypan blue (dead cells: % ± SD). Each dose-
experiment was performed in triplicate. 
Table 10.2. Effect of rRIFN-y on growth of tumor CC531 in a subrenal capsule assay. 
Treatment 
PBS 
rRIFN-y 
n 
10 
10 
Tumor weight (mg ± SD) 
30.6 ± 7.2 
18.5 ± 6.5 
p 
<0.05 
rRIFN-y therapy (5 x 1o' U/kgjday, i.v.) was given for 5 days, starting on the day of implantation. Each 
group contained 5 animals of which both kidneys were used for tumor implantation. 
control rats amounted to 30.6 ± 7.2 mg and to 18.5 ± 6.5 mg in the group treated 
with rRIFN-y. The results obtained with rRIFN-y in the liver metastases model in 
two separate experiments are shown in Table 10.3. An impressive inhibition of tumor 
development as a result of treatment with rRIFN-y was observed; in both experi-
ments the difference between the control and rRIFN-y group was highly significant 
(p<0.001). In experiment I, 5 animals from the control group having more than 60 
nodules were killed on the day of inspection, the remaining 2 animals with 24 liver 
metastases and all animals from the rRIFN-y treated group were kept alive. The 
controls survived for 52 and 55 days; the rRIFN-y treated animals survived for 88, 91, 
95, 95 and more than 100 days (2x), respectively. 
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Table 10.3. Effect of rRIFN-y on CC531 tumor growth in a liver metastases modeL 
Exp I 
Exp II 
Treatment 
PBS 
rRIFN-y 
PBS 
rRIFN-y 
Number of liver metastases 
~~<~<~<~<~<~<00 
~~~~~~7 
4, 9, 20, 20, <00 
0, 0, 0, 1, 2, 10 
Liver metastases were evoked by injection of 5 x Hf CC531 tumor cells into the portal vein. rRIFN-y (5 
x l(f U/kg/day, i.v.) was given for 5 days, starting on the day of cell injection. Metastases were counted 
after 30 days. 
Discussion 
In a previous communication we reported on the susceptibility of tumor CC531 for 
virus-induced rat IFN-ajB in the SRCA and the failure to treat artificial liver 
metastases with this preparation (17). The results from the present study indicate that 
rRIFN-y has impressive antitumor capacity in both in vivo models. In contrast, 
rRIFN-y, in the dosages used, had no effect on CC531 in vitro. Consequently, it is 
likely that tumor inhibition evoked by rRIFN-y in vivo was indirect and due to acti-
vation of the immune system of the host, either or not combined with an enhanced 
susceptibility of the tumor cells. Such an enhanced sensitivity has recently been 
demonstrated for monocyte-mediated cytolysis by Feinman (22). Alternatively, in-
creased destruction of tumor cells by rRIFN-y activated monocytes, independent of 
an effect on target cells has been reported repeatedly (7,15,23-25). Enhancement of 
NK cell activity may have been a second mechanism for the antitumor activity of 
rRIFN-y. Improved NK-mediated cytotoxicity by rRlFN-y has been reported earlier 
by others (10,11). NK cells are known to be most effective against a small tumor em-
boli (26,27), which may provide a likely explanation for the observed discrepancy 
between the moderate effect of rRIFN-y in the SRCA, where tumor cubes were used, 
and the marked effect in the liver metastases model. An additional explanation for 
the surprisingly high effectiveness of rRIFN-y in the liver model hinges on an im-
portant antitumor role of Kupffer cells. Recent findings by Pearson et a!. (28), also 
obtained in a rat liver metastases model, suggest that the activity of Kupffer cells may 
determine the outcome of metastases growth in the liver for a great deal. Kupffer cell 
stimulation by Corynebacterium parvum significantly reduced the number of liver 
metastases; whereas depression of Kupffer cell-activity by silica, gadolinium and 
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injection of rRIFN-y within 24 hours leads to an increased expression of class IT his-
tocompatibility antigens on Kupffer-like cells in the liver, indicating the presence of 
high-affinity receptors for rRIFN-y and rapid post-receptor action on cell metabolism 
(unpublished results). Analogous to the effects of IFN-y on macrophages, namely 
increased class IT antigen expression associated with improved phagocytosis (8,15), it 
may also have the capacity to enhance the antitumor activity of Kupffer cells in 
addition to the increased antigen expression observed. 
In conclusion, the present study has shown that rRIFN-y exerts a marked anti-
proliferative effect on tumor CC531, especially in a situation where a low tumor 
burden was involved. The finding that rRIFN-y had no effect on the tumor in vitro 
suggests that the antitumor activity in vivo was indirect and probably mediated by an 
activated immune system. 
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Chapter 11 
ANTITUMOR ACTIVITY OF rTNF ON COLON CANCER IN RATS IS 
PROMOTED BY rRIFN-y; TOXICITY IS REDUCED BY INDOMETHACIN 
Abstract 
The activity and toxicity of rMuTNF, alone or combined with rRIFN-y, was tested in 
rats bearing a weakly immunogenic colon adenocarcinoma, implanted subcutaneously 
(s.c.) or under the renal capsule. A single intravenous (i.v.) injection of 40J,£gjkg of 
rMuTNF was lethal to non-tumor bearing rats in 3 to 5 hr, whereas 10J.£g/kg was not. 
Doses of 4J.£g/kg rMuTNF were well tolerated when given daily for one week. The 
most prominent toxic feature of rMu1NF was hemorrhagic colitis which could be 
alleviated by intraperitoneal (i.p.) pretreatment with indomethacin (10mg/kg). 
rMuTNF (10 mgjkg) injected s.c. into tumors led to retardation of growth in 20% of 
the rats. Combined with 4x10S U/kg rRIFN-y, which on its own had no effect, 
response was found in 50% of tumors with 2 out of 20 tumors showing regression. 
Combined treatment with rMuTNF (2J.£g/kg) and indomethacin (10mg/kg) had a;n 
effect similar to that of rMuTNF alone (25 ± 9mg vs 24 ± 7mg). Under protection of 
indomethacin the rMuTNF dose could be increased to 40J.£g/kg, however, without in-
crease of antitumor effects. 
This chapter was published in Int J Cancer 40: 550-553, 1987. 
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Introduction 
TNF is a protein mainly produced by activated macrophages, originally demonstrated 
in the serum of animals treated with Bacillus Calmette-Guerin and endotoxin (1). 
TNF has been functionally defined by its cytostatic and cytolytic properties against 
certain tumor cell types in vitro and by its its capacity to cause hemorrhagic necrosis 
of animal and xenografted human tumors in vivo (2). TNF belongs to a group of 
molecules with related structure exhibiting various biological activities, reminiscent of 
the interferon system (3). Lymphotoxin, also designated as TNFJ3, which is a product 
of activated lymphocytes (4), belongs to the TNF family, whereas cachectin, produced 
by macrophages (5), is identical to TNF. Under physiological conditions TNF most 
likely plays a regulatory role during infection ( 6). This notion is also evidenced by the 
finding that TNF can enhance the phagocytic capacity and antibody-dependent cyto-
toxicity of neutrophilic granulocytes and can stimulate their adherence to endothelial 
cells (7,8). It has also been shown that 1NF can induce the expression of MHC class 
II antigens on macrophages (9). The antitumor effects of 1NF may be partly related 
to these effects of TNF on neutrophils and macrophages. 
Recently, recombinant human and mouse TNF have become available and their 
antitumor capacities clearly demonstrated (10-13). In some tumor models the effect of 
TNF was markedly enhanced by simultaneous administration of interferons, notably 
IFN-y (13-15). 
We have previously reported an antiproliferative capacity of IFN and IFN-inducers 
using a transplantable colon adenocarcinoma in inbred rats (16,17). In the present 
study this clinically relevant tumor model was employed to determine the therapeutic 
capacity and toxicity of rMuTNF given alone or in combination with rRIFN-y. 
Materials and methods 
Animals Male rats of the inbred WAG strain were used. The animals were bred 
under specific pathogen-free conditions, weighed 200-250 g and were 10-12 weeks old. 
Tumor A 1,2 dimethylhydrazine-induced, moderately differentiated colon adeno-
carcinoma (CC531), transplantable in syngeneic WAG rats, was used (16). The tumor 
is weakly immunogenic as determined by the immunization-challenge method of 
Prehn and Main (18). In the present experiments the tumor was in its 18th passage. 
Subcutaneous implantation Under ether anesthesia tumor cubes measuring 2mm 
were implanted in the left flank of WAG rats. Tumor growth was assessed by 
measuring with calipers the two largest perpendicular diameters at regular time 
intervals. The average diameter was taken as measure of tumor size. 
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Subrenal capsule assay (SRCA) WAG rats were anesthetized with ether, a median 
laparotomy was performed and both kidneys exp0sed. A small incision was made in 
the renal capsule and a tumor cube of 6-8mg was implanted and pushed up to the 
upper kidney pole. The animals were killed after one week and the tumors in both 
kidneys were enucleated and weighed. 
TNF Details of the production of recombinant DNA-derived murine TNF 
(rMuTNF) have been published elsewhere (19). The preparation used was over 99% 
pure, contained 72 x 106 units per mg protein and less than SOng endotoxin per mg 
protein. 
IFN-r Recombinant DNA-derived rat IFNy (rRIFN-y) was a gift from Dr. P.H. 
van der Meide (TIRI-1NO, Rijswijk, The Netherlands). Details of cloning, expression 
and purification of rRIFN-y have been published by Dijkema et al. (20). The prepara-
tion used in the present experiments contained 106 units per mg protein and had a 
purity of 25%. 
Indomethacin Indomethacin was obtained as a powder, dissolved in PBS and 
injected intraperitoneally (i.p.) at a dose of lOmgjkg body weight in a volume of 
0.5ml. 
Experimental design In the first series of experiments non-tumor bearing rats were 
treated i.v. with different dosages of rMuTNF (1-lOOOJ.Lg/kg) in order to assess its 
toxicity. In follow-up studies rMuTNF was combined with indomethacin in order to 
abrogate major side effects. Each experimental group contained at least three 
animals. To study the effect of intralesional injected rMuTNF the subcutaneous tumor 
model was used. Pieces of tumor CC531 were implanted in the flank of WAG rats. 
After 20 days, animals bearing tumors with a diameter between 1-l.Scm were 
randomized into three groups of 10 animals each. After randomization, intratumoral 
injections were given of 40J.Lg/kg rMuTNF, alone or in combination with 4 x lOS U /kg 
rRIFN-y, on days 0, 10 and 15. The injected volume always amounted to O.lml. The 
experiments were performed 2 times. 
Previously, we studied the effect of rRIFN-y on tumor growth using the same 
CC531 model (21). Since no antitumor effects were found at a dosage of 4 x lOS U/kg 
rRIFN-y, this experiment was not repeated in the present study. 
The SRCA was used to investigate the possible interference of indomethacin with 
the antiproliferative capacity of rMuTNF. It was also employed to see whether the 
therapeutic effect of rMu1NF could be enhanced by increasing the dose under indo-
methacin protection. Doses of 8 or 40J.Lg/kg rMuTNF were given i.v. on days 0, 2 and 
4. Indomethacin was given i.p. at a dosage of lOmg/kg, 1 hr before the administration 
of rMuTNF. The assay was read 1 week after tumor implantation. Each experimental 
group contained 5-6 animals. 
Statistical analysis Results were analyzed using Chi-square and Student's t test. 
Differences were considered to be significant at p < 0.05. 
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Results 
Toxicity studies 
A single i.v. injection of 1000, 400 or 40p.gjkg of rMuTNF was uniformly lethal within 
3-5 hr. The animals became diarrheic within 1 hr, blood appearing in the feces rapidly 
thereafter. At autopsy, the most prominent finding was hemorrhagic enteritis which 
was mainly restricted to the colon. A single dose of 8J,.£gjkg was well tolerated and 
could be repeated on alternate days without leading to hemorrhagic colitis. Dosages 
of 4J..£g/kg could be given daily. The lethal effect of 40J..£g/kg rMuTNF could be abo-
lished by pretreating animals with 10mgjkg indomethacin i.p., 1 hr before injection of 
rMuTNF. Animals receiving this combination developed only mild diarrhea; this 
treatment could be repeated 3 times on alternate days. However, it repeatedly led to 
excessive wasting and a weight loss of 25% within one week was not exceptional. 
Effect of intratumoral rMuTNF on subcutaneous tumor growth 
The growth curves of the tumors treated by intratumoral injection with rMuTNF, 
alone or in combination with rRIFN-y, are shown in Figure 11.1. The mean tumor 
diameter on day 21 was 2.7 ± 0.4cm for the controls, 2.4 ± 0.3cm for the group 
treated with rMuTNF and 1.9 ± 0.8cm for the group treated with rMuTNF and 
rRIFN-y. The difference between the latter group and the controls at this particular 
point (day 21) was significant (p<0.01; chi-square). Remarkably, some tumors were 
clearly inhibited in growth, whereas others hardly showed any response. This was 
found in both experimental groups. Intratumoral injection of rMuTNF produced only 
mild toxicity in some animals and this was not increased when rMuTNF was com-
bined with rRIFN-y. 
Table 11.1. Effect of intratumoral injection of rMuTNF and rRIFN-y on tumor CC531. 
Treatment Progression Arrest Regression 
Controls 100% 0% 0% 
rMuTNF 80% 20% 0% 
rMuTNF +rRIFN-y 50% 40% 10% 
Treatment was started 3 weeks after s.c. tumor implantation when the tumors were between 1 and 1.5 
em in diameter. rMuTNF was given at a dose of 10 ~-tg and rRIFN-y at a dose of 1o" units on d~y 0, 10 
and 15. Each group contained 20 rats. 
Using the same treatment protocol, the study was repeated with 20 animals per 
group. The results are summarized in Table 11.1. They are grouped according to the 
effect of one or more intratumoral injections on tumor growth, i.e. progression, arrest 
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Figure 11.1. Effect of intratumoral injections with rMuTNF (l011g) and rRIFN-y (lOS U) on CC531 
tumor growth. Twenty days after s.c. tumor implantation treatment was started (day 0, 10 and 15). 
Controls were injected with PBS. Each group consisted of 10 animals. On day 21 there was a significant 
difference between the control group and the group treated with rMuTNF and rRIFN-y (p<O.Ol). 
tumor diameter (em) 
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or regression. If a tumor stopped growing for at least one week this was classified as 
"arrest". "Regression" indicates that tumor size was reduced by 50% or more. The 
results indicate that treatment with rMu1NF led to arrest of growth in 20% of the 
cases but not to tumor regression. Only combined treatment of rMu1NF and rRIFN-
Y gave rise to regression. In one case the tumor seemed to have disappeared 
completely; however, it recurred after 14 days and was insensitive to further 
treatment. The combined treatment with rMu1NF and rRIFN-y had an overall res-
ponse rate of 50%, whereas rMu1NF alone had a response rate of 20% (p<O.OOl; 
chi-square). 
Combined effect of rMuTNF and indomethacin 
In the course of the toxicity studies mentioned above, it was found that indomethacin 
could alleviate the toxic side-effects of rMu1NF. The SRCA was used to investigate 
whether the combined administration of these agents would interfere with the 
antiproliferative potential of rMu1NF. The results are shown in Table 11.2. Indo-
methacin alone had no effect on tumor growth, whereas treatment with rMu1NF pro-
duced a significant inhibition of tumor development (p<O.OOl). The combined ad-
ministration of both agents had an effect similar to that of treatment with rMu1NF 
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Table 11.2. Effect of indomethacin and rMuTNF on tumor CC531. 
Treatment Tumor weight p 
Controls 48±13 
Indomethacin 40 ± 8 ns 
rMuTNF 24 ± 7 <0.001 
Indomethacin + rMu~ 25 ± 9 <0.001 
rMuTNF was given i.v. at a dose of 8!-Lg/kg on days 0, 2 and 4 in a SRCA. Indomethacin (10mg/kg) was 
given i.p. 1 hr before rMuTNF. After 1 week, tumors were enucleated and weighed. Groups consisted of 
6 animals, from each of which both kidneys were used. Tumor weight in mg: mean ± SD 
alone, indicating that indomethacin neither abrogated nor potentiated the antitumor 
activity of rMuTNF. 
Antiproliferative effects of high doses of rMuTNF 
Pretreatment with indomethacin allows rMuTNF to be administered in doses which 
would have been lethal when given alone. The SRCA was employed to investigate 
whether such high dosages would lead to a stronger inhibition of tumor growth. The 
results are shown in Table 11.3. A dose of 40J.Lg/kg appeared to produce the same 
antiproliferative effect as a dose of 8J.Lg/kg. 
Table 11.3. Effect of different doses of rMuTNF on tumor CC 531. 
Treatment Tumor weight p 
Controls 45 ± 8 
8 1-1g/kg rMuTNF 33 ± 5 <0.001 
40 1-1g/kg rMuTNF 34±11 <0.05 
Treatment with rMuTNF was given on days 0, 2 and 4 in a SRCA After 7 days tumors were enucleated 
and weighed. Each group contained 5 animals, from each of which both kidneys were used. Tumor 
weight in mg: mean ± SD. 
Discussion 
Our study has shown that rMuTNF has antitumor activity against a rat colon adeno-
carcinoma when administered by intratumoral or intravenous injection. Local admini-
stration was only moderately effective but could be significantly improved when 
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stration was only moderately effective but could be significantly improved when 
rMuTNF was combined with rRIFN-y. These results are in agreement with earlier 
observations on the in vivo effects of partially purified and rMuTNF (11,22). 
The toxicity of rMuTNF was a serious problem and was higher than anticipated on 
basis of results obtained in nude mice (13). A dose of 25p.g rMuTNF was not toxic for 
nude mice, whereas in our experiments a lOp.g dose was lethal for a 250g rat. This 
susceptibility was not a particular feature of the WAG strain used in the current 
experiments; pilot studies performed using the inbred BN rat strain gave similar 
results (data not shown). In both strains the predominant pathological finding was a 
severe hemorrhagic colitis, shock being the most likely cause of death. It has been 
shown that TNF can induce the production of prostaglandin E2 in cultured fibroblasts 
(23). This observation, together with the finding that TNF has a marked effect on 
endothelial cells (24,25) led us to the hypothesis that the toxic effects of rMuTNF 
were due to exaggerated production of prostaglandins by vascular cells with the 
ensuing modulation of platelet aggregation and vascular tonus. Indirect evidence that 
this hypothesis might be correct is provided by our results obtained with the pros-
taglandin-inhibitor indomethacin. The toxic side-effects of rMuTNF were considerably 
reduced by pretreatment with indomethacin and mortality did not occur. However, 
the excessive wasting of animals treated with high doses of rMuTNF was not abo-
lished by treatment with indomethacin. It is quite possible that the wasting was due to 
the cachectin-like activity of rMuTNF. Cachectin is able to suppress the activity of 
lipoprotein-lipase in adipocytes and is identical to TNF (5). It has been suggested that 
some of the metabolic disturbances, including cachexia, seen in cancer patients, may 
be due to the activity of endogenously produced TNF (3). 
Indomethacin, at the dosage used, had no effect on growth of tumor CC531. Inhi-
bition of intestinal rat tumors by indomethacin has been reported by several authors; 
however, other workers did not observe such an effect (26-28). Indomethacin did not 
interfere with the antitumor activity of rMuTNF and allowed relatively high doses of 
rMuTNF to be given. However, increasing the dose did not lead to an improvement 
of the results. Balkwill et al., using human tumor xenografts in nude mice, have 
reported similar results for tumors that were sensitive to TNF treatment at a low dose 
(13). Increasing the dose did not lead to a better antiproliferative effect for these 
tumors. In contrast, tumors which were resistant to TNF became responsive when the 
dose was increased. 
The synergistic activity of rMuTNF and rRIFN-y could be expected from the results 
of other studies in which both cytokines were used (11,13). Different mechanisms may 
contribute to this effect. There may be a direct cytotoxic effect which is reinforced by 
using both cytokines. Fransen et aL (14) demonstrated the synergism of rMuTNF with 
IFN-y on different cell lines in vitro. It has been demonstrated that IFN-y can enhan-
ce the expression of tumor necrosis factor receptors on various cell types (29); this 
117 
may render cells more susceptible to TNF treatment. Furthermore, IFN-y may aug-
ment the production of endogenous TNF in response to endotoxin by enhancing TNF-
gene transscription and mRNA translation (30,31). Although we did not find a stron-
ger antiproliferative response to higher doses of rMuTNF, an extended period of 
treatment with a low dose may certainly be more effective. Finally, the synergistic 
activity of rMuTNF and rRIFN-y may be explained by indirect mechanisms of action 
exerted by host cells. IFN-y has been shown to activate macrophages, thereby en-
hancing tumoricidal activity (32) and other defensive functions (21,33). Previously, we 
could not find an antitumor effect of lower dosages of rRIFN-y in the same model 
(21). It is conceivable that the dose of rRIFN-y used was near a threshold level that 
can be exceeded by adding another cytokine, such as rMuTNF. 
Our results provide further evidence for the potential of TNF in tumor therapy. 
Improvement of the therapeutic efficacy of TNF is likely to be obtained by the com-
bined administration of TNF with IFNs, especially IFN-y. Our present results and 
those of others clearly point in the direction of such a multimodality approach in 
which there may be a place for indomethacin to limit toxicity. 
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GENERAL DISCUSSION 
The experimental work with rRIFN-y in rodents, presented in this thesis, has clearly 
demonstrated that this cytokine can exert pleiotropic activities in vivo. rRIFN-y was 
found to stimulate the activity of NK cells, T cells and macrophages (Chapter 4), to 
increase MHC class II antigen expression on various cell types (Chapter 5), and to 
inhibit tumor growth, alone (Chapter 10) or in combination with 1NF (Chapter 11). 
The results of these experiments are in agreement with reports on the effects of riFN-
Y in mice and man (1). 
The feasibility to manipulate graft rejection with rRIFN-y was studied. It was 
found that low dosages of rRIFN-y had no effect on the outcome of graft survival, 
while high dosages were associated with serious toxicity and mortality limiting the use 
of rRIFN-y. Hemodynamic and immunological changes due to the surgical procedure 
and blood loss might have amplified rRIFN-y toxicity (2). 
In the physiological process of inflammation, lymphoid cells are capable to focus 
their secretory apparatus towards the site of immunostimulation before cytokines are 
released, thereby producing high concentrations of cytokines at the centre of immune 
responses (3,4). It remains to be determined whether these high cytokine concentra-
tions can be achieved adequately in the pericellular environment by systemic admini-
stration of cytokines. 
In man the limitations of systemic treatment by intravenous infusion have been 
reported repeatedly. Clinical studies with IFN-y (1), IL-2 (5) and TNF (6) have 
demonstrated serious dose-limiting toxicities, such as hypotension and pulmonary 
insufficiency. As discussed below new techniques of cytokine administration must be 
designed that reduce toxicity, while maintaining efficacy. In addition, the availability 
of monoclonal antibodies against cytokines may help to clarify and to manipulate 
immune reactions. 
rRIFN-y induces MHC class II antigen expression on different cell types, including 
interstitial dendritic-like cells and endothelial cells. These cells have the capacity to 
stimulate allogeneic lymphocytes by presentation of MHC class II antigens (7,8). We 
found that a significant increase in the number of dendritic and endothelial cells 
expressing MHC class II antigens in a graft had no effect on rejection by unmodified 
recipients. Thus enhancement of MHC class II antigen expression within a graft does 
not imply increased immunogenicity. Apparently, the normal amount of MHC class II 
antigen expressing cells within a graft meets the requirements to activate allogeneic 
helper T-cells in an unmodified rejection process most sufficiently. However, in those 
settings where the immune system of the recipient is modified, e.g. the afferent 
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pathway suppressed by CyA or the efferent pathway stimulated by sensitization, an 
increase of allogeneic MHC class II antigens accelerates rejection. In case of CyA 
immunosuppression the increase of allogeneic MHC class II antigens may annul the 
effect of CyA which inhibits the production of lymphokines responsible for MHC 
antigen expression (9). If the recipient is sensitized, effector mechanisms may be facil-
itated by an increase of allogeneic MHC class II antigen expression on target cells. 
Clearly, MHC class II antigens play a role in the process of antigen recognition and 
rejection. However, in our experiments it was not possible to manipulate the rejection 
process with rRIFN-y, although a significant increase of MHC class II antigen 
expression was found. 
In this thesis also the antitumor activity of rRIFN-y was studied. It was found that 
rRIFN-y treatment could reduce the number of liver metastases in a colon adenocar-
cinoma model, while rRIFN-y had no effect on tumor growth in vitro. These findings 
strongly suggest that the antitumor effect of rRIFN-y was caused by indirect 
mechanisms, such as activation of host effector cells (described in Chapter 4). It has 
been demonstrated that NK cells that reside in liver and lung have the capacity to 
reduce the take of tumor cells (10). In our experiments the antitumor effect of 
rRIFN-y may indeed be explained by stimulation of NK cell cytotoxicity. 
rRIFN-y and rTNF were found to have a synergistic antitumor effect on colon 
adenocarcinoma in a subcutaneous model. In vitro studies have indicated additional 
effects of both cytokines. Several mechanisms may explain this finding. In addition to 
augmentation of direct cytotoxicity, IFN-y may induce the expression of TNF-
receptors on tumor cells, increase activation of effector cells stimulated by TNF and 
induce the release of other cytokines that act synergistically with TNF (for review see 
ref. 4). 
Importantly, the current experiments have demonstrated that combinations of 
cytokines, such as IFN-y and TNF, may act synergistically in the treatment of 
malignancies. However, toxic side-effects may be reinforced too. As shown in our 
model, local administration by intralesional injection reduces cytokine toxicity. As this 
technique has its limitations for application in patients with disseminated cancer, new 
techniques must be developed to administer cytokines locally at the centre of anti-
tumor reactions. Several techniques are currently being investigated. One of these is 
focused on genetic engeneering of tumor infiltrating lymphocytes (TIL) to increase 
their cytokine production. Assuming that these manipulated cells will home 
preferentially at the tumor site, locally high concentrations of cytokines may be 
induced. However, the feasibility of this technique remains to be determined. Local 
administration may also be achieved by the use of cytokine-containing liposomes, 
alone or in combination with monoclonal antibodies directed against target cells. 
Further, treatment schedules are being designed that combine the use of exogenous 
recombinant cytokines with the application of biological response modifiers, agents 
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that are able to induce endogenous cytokine production. And last but not least 
molecular biology technologies may improve the molecular design of cytokines and 
produce new molecules with increased specific activity (11). 
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SUMMARY 
IFN-y was one of the first cytokines produced by recombinant DNA technology. After 
the production of recombinant DNA derived mouse and human IFN-y, recombinant 
DNA derived rat IFN-y became available. With this species-specific cytokine it has 
become possible to study biological effects of IFN-y in rats. Compared to the mouse 
model, the rat model is more suitable to study activities of IFN-y in tumor and organ 
transplantation experiments, since these experiments are technically far less deman-
ding in rats. In this thesis multiple biological effects of rRIFN-y are studied in 
transplantation and tumor experiments in rats. 
In Chapter 1 a brief introduction on immune reactions is given with emphasis on 
cell signalling. 
A review on IFN-y is presented in Chapter 2. Several aspects of IFN-y are being 
discussed, varying from the molecular biology to clinical studies. 
In Chapter 3 the objectives of investigation are presented. 
In Chapter 4 various immunoregulatory activities of rRIFN-y in vivo are demon-
strated. rRIFN-y significantly increases the activity of NK cells, T cells and peritoneal 
phagocytes. High doses of rRIFN-y were toxic to .rats leading to deterioration of their 
condition. This finding may reflect the flu-like symptoms observed in patients treated 
with IFN-y. The rapid physiologic clearance of IFN-y is well-documented. Conside-
ring the toxicity of high doses of IFN-y, this rapid clearance mechanism may protect 
the organism against side-effects of its own products. 
In Chapter 5 the capacity of rRIFN-y to induce MHC class II antigen expression 
on various cell structures is demonstrated. Different rat strains showed similar 
patterns of induction, except for endothelial cells. Induction of MHC class II antigen 
expression on endothelial cells was found in LEW, but not in BN or WAG rats. 
Although rRIFN-y was found to stimulate various immune parameters, rRIFN-y 
treatment of recipients had no effect on graft rejection (Chapter 6). Administration of 
high doses of rRIFN-y to transplant recipients immediately after operation led to a 
high mortality (75%). 
Since MHC class II antigens are known to be involved in helper T cell activation, 
the relevance of increased MHC class II antigen expression on allografts prior to 
transplantation was studied. Pretreatment of BN rats with rRIFN-y increased the 
number of dendritic-like cells within cardiac grafts before transplantation to LEW 
recipients (Chapter 7); in addition, pretreatment with rRIFN-y of LEW rats increased 
MHC class II antigen expression on dendritic-like cells as well as on endothelial cells 
before transplantation to WAG rats. However, in none of these experiments pre-
treatment with rRIFN-y had an effect on acute graft rejection. These findings indicate 
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that the normal amount of MHC class IT antigens within a graft suffices to activate T 
cells to a maximum level. 
Experiments were performed in which the host immune system was manipulated 
prior to transplantation of skin grafts of rRIFN-y pretreated donors (Chapter 9). 
Recipients were treated either by short-term immunosuppression (CsA) or by 
sensitization (donor specific skin transplantation). In both experiments accelerated 
rejection of rRIFN-y pretreated skin grafts was found. These findings may be 
explained by alterations in the afferent as well as the efferent pathway of the host 
immune responses. MHC class IT antigen enriched grafts may have stimulated helper 
T cells in weakly immunosuppressed recipients and cytotoxic T cells in sensitized reci-
pients. Thus, upregulation of MHC class IT antigen expression does not affect re-
jection by unmodified recipients, but accelerates rejection by immunomodulated reci-
pients. 
It was found that rRIFN-y inhibited tumor growth in vivo, while no direct antipro-
liferative effects of rRIFN-y were demonstrated in vitro (Chapter 10). This finding 
suggests that indirect antitumor mechanisms are activated by rRIFN-y, such as those 
described in Chapter 4. The outcome of these experiments supports the concept of 
immunotherapy, which is based on the assumption that stimulation of the host's 
immune system may lead to elimination of tumor cells. 
TNF is a cytokine of which immunoregulatory and antitumor activities have been 
identified. Combined local treatment with rRIFN-y and TNF was found to have a 
synergistic antitumor effect (Chapter 11). Further studies on treatment schedules and 
routes of administration have to be performed to determine the strongest antitumor 
activity of various combinations of cytokines. 
In Chapter 12 a general discussion is presented. It is emphasized that systemic 
toxicity due to increased IFN-y serum concentrations limits its use to manipulate 
immune reactions at a local level. Therefore, new techniques must be developed by 
which it will be possible to increase local concentrations of IFN-y without inducing 
significant elevations of serum levels. With the availability of rRIFN-y the rat model 
may offer perspectives for further cytokine research. 
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SAMENVATIING 
Cytokines zijn eiwitten die met name geproduceerd worden door cellen van het 
immuun systeem. V erschillende cytokines zijn geidentificeerd en door recombinant 
DNA technieken beschikbaar gemaakt voor onderzoek. Interferon-y was een van de 
eerste cytokines dat in grate hoeveelheden werd geproduceerd en waarvan, in vitro, 
meerdere immunoregulerende en antitumor eigenschappen werden vastgesteld. Het 
be lang van IFN -y voor immunoregulerende en antitumor processen in vivo is echter 
niet duidelijk. Dankzij de ontwikkeling van recombinant ratte-IFN-y (rRIFN-y) is het 
mogelijk geworden de funkties van dit cytokine bij de rat te analyseren. In dit 
proefschrift worden de resultaten van een dergelijke analyse gepresenteerd. 
In het eerste hoofdstuk worden recente ontwikkelingen op het gebied van de 
cellulaire immunologie en de recombinant DNA technologie beschreven. Het belang 
van deze ontwikkelingen voor klinische vormen van immunomodulatie, zoals in de 
transplantatie-geneeskunde en in de oncologie, wordt toegelicht. Tot op heden vormt 
het aspecifieke karakter van therapie gericht op immunomodulatie een belangrijke 
tekortkoming. Een beter inzicht in de funktie en het werkingsmechanisme van cytoki-
nes zou mogelijkheden kunnen bieden voor selektieve manipulatie van het immuun-
systeem. In het eerste hoofdstuk wordt een korte inleiding gegeven in de immuno-
logie, waarbij de verschillende celtypen en cytokines die betrokken zijn bij 
immunologische reakties nader worden gedefinieerd. 
In het tweede hoofdstuk wordt een literatuuroverzicht gegeven van IFN-y. De 
ontdekking van interferonen en de indeling in een drietal klassen (IFN-a, -13 en -y) 
wordt beschreven. Uiteenlopende aspecten van IFN-y worden besproken, varierend 
van de moleculaire biologie tot de eerste resultaten van klinische onderzoeken. 
In het derde hoofdstuk worden de doelstellingen van de verschillende experimenten 
genoemd. 
De eerste experimenten waren gericht op het aantonen van de immunomoduleren-
de effecten van rRIFN-y bij de rat (Hoofdstuk 4). Behandeling met rRIFN-y leidde 
tot haematologische veranderingen, waaronder een reduktie van het aantal perifere 
bloedcellen en beenmergcellen. Wij stelden vast dat rRIFN-y leidt tot een toename 
van de aktiviteit van NK cellen, fagocyterende cellen en T cellen. 
Drie rattestammen werden gebruikt om het effect van rRIFN-y op de expressie van 
MHC klasse II antigenen te bestuderen (Hoofdstuk 5). Bij alle rattestammen werd in 
meerdere organen een sterke toename van klasse II positieve, dendrietachtige intersti-
tiele cellen gevonden; in organen van LEW-ratten werd tevens induktie van MHC 
klasse II antigenen op endotheel van grate bloedvaten gezien. Deze bevinding stemt 
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overeen met de variatie in induktiepatronen die worden waargenomen bij acute 
afstotingen. 
Het effect van rRIFN-y op het proces van afstoting werd bestudeerd in een 
harttransplantatie model (BN hart in een WAG of BN hart in een LEW ontvanger), 
zoals beschreven Hoofdstuk 6. Harttransplantatie werd gevolgd door behandeling van 
de ontvanger met rRIFN-y. Deze behandeling had geen effect op het afstotings-
proces; bij toediening van hoge doseringen rRIFN-y werd een ernstige morbiditeit en 
mortaliteit (tot 75%) geconstateerd. 
Wij stelden vast dat rRIFN-y de expressie van MHC klasse II antigenen kan 
induceren (Hoofdstuk 5). Deze antigenen spelen een belangrijke rol in de stimulatie 
van CD4 T cellen (T helper cellen). Via donor-voorbehandeling met rRIFN-y werd 
de expressie van MHC klasse II antigenen versterkt, alvorens een harttransplantatie 
werd uitgevoerd. Deze voorbehandeling leidde tot een significante toename van inter-
stitiele cellen met MHC klasse II antigen expressie in het hart van BN-ratten; bij 
LEW-ratten werd bovendien de novo induktie van MHC klasse II antigenen op vaat-
endotheel gevonden. Transplantatie van dergelijke voorbehandelde harten naar ratten 
van een andere stam had echter geen effect op het beloop van het acute afstotings-
proces (Hoofdstuk 7 en 8). Deze bevindingen suggereren dat in een normaal trans-
plantaat reeds voldoende MHC klasse II antigenen aanwezig zijn om in een niet 
voorbehandelde ontvanger een afstotingsreaktie volledig in gang te zetten. 
In de volgende experimenten werd de immuunstatus van de ontvanger gemanipu-
leerd (Hoofdstuk 9). In een huidtransplantatie model (LEW huid in een WAG 
ontvanger) werd het effect van rRIFN-y donor voorbehandeling bestudeerd na 
sensitisatie of immunosuppressie van de ontvanger. In beide modellen werd een 
significante versnelling gevonden van het afstotingsproces, hetgeen het belang 
aangeeft van een toename van MHC klasse II antigenen voor de gemodificeerde 
afstoting. Mogelijk vormt de toename van MHC klasse II antigenen in het immuno-
suppressie-model een sterkere immunogene stimulus voor CD4 T cellen in de afferen-
te component van de afstoting; in het sensitisatie-model kan een toename van allo-
antigenen het aantal target cellen verhogen, hetgeen een sterkere stimulus vormt voor 
reeds aanwezige effector cellen. 
Antitumor effecten van rRIFN-y werden in vitro en in vivo bestudeerd (Hoofdstuk 
10). De groei van een celsuspensie van het colon adenocarcinoom CC531 kon in vitro 
niet worden beinvloed door behandeling met rRIFN-y. In het diermodel werd echter 
wel een antitumor effect gevonden. rRIFN-y behandeling van WAG-ratten met een 
CC531 tumor-implantaat onder het nierkapselleidde tot een significante remming van 
tumorgroei. In een levermetastasen model werd vastgesteld dat behandeling met 
rRIFN-y, gestart na injektie van CC531 tumor cellen in de vena portae, leidde tot 
een significante vermindering van het aantal metastasen. Deze bevindingen suggere-
ren dat het antitumor effect van rRIFN-y op indirekte wijze tot stand kan komen, 
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mogelijk door veranderingen aan de target-cellen en/ of door veranderingen in de 
afweer van de gastbeer tegen tumorcellen, zoals die van de Kuppfer cellen of NK 
cellen (vgl. Hoofdstuk 5). 
Tot slot werd bet effect van rRIFN-y in combinatie met TNF bestudeerd in bet 
colon adenocarcinoom model. Door injektie van de verschillende cytokines in subcu-
taan geimplanteerde CC531 tumoren kon een synergistiscb effect van TNF en rRIFN-
Y worden aangetoond (Hoofdstuk 11). 
Hoofdstuk 12 bevat een algemene discussie over de resultaten van de verschillende 
experimenten. De bevindingen over de immunomodulerende en antitumor eigen-
schappen van IFN-y in het rattemodel stemmen overeen met die uit studies in mui-
zenmodellen en in de mens. Het is duidelijk dat IFN-y slechts een van de vele cyto-
kinen is die een rol spelen in immunologische reakties en dat manipulatie met IFN-y 
aileen geen mogelijkheden biedt tot beinvloeding van acute afstotingsreakties. 
Onderzoek met monoclonale antilichamen tegen IFN-y kan nadere informatie geven 
over de rol van dit cytokine in de regulatie van immunologische processen. Ten 
aanzien van de antitumor werking van IFN-y zal verder onderzoek verricht moeten 
worden naar de mogelijkheden van lokale toediening en verhoging van de antitumor 
effectiviteit door combinatie met andere middelen, zoals cytokines (TNF) of 
chemotberapeutica. Het in dit proefschrift beschreven model biedt goede mogelijk-
heden voor verdere studies op dit gebied. 
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